ljpc-10q_20210630.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-21-041197.txt : 20210805 0001564590-21-041197.hdr.sgml : 20210805 20210805080126 ACCESSION NUMBER: 0001564590-21-041197 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 211146400 BUSINESS ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-715-3600 MAIL ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 ljpc-10q_20210630.htm 10-Q ljpc-10q_20210630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number: 1-36282

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

California		33-0361285
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

201 Jones Road, Suite 400, Waltham, MA		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 715-3600

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

LJPC

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 23, 2021, there were 27,488,137 shares of common stock outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements	1

Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020	1

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	2

Condensed Consolidated Statements of Shareholders’ Deficit for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited)	3

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited)	4

Notes to Condensed Consolidated Financial Statements (Unaudited)	5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3. Quantitative and Qualitative Disclosures about Market Risk	26

Item 4. Controls and Procedures	26

PART II. OTHER INFORMATION	27

Item 1. Legal Proceedings	27

Item 1A. Risk Factors	27

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 3. Defaults upon Senior Securities	27

Item 4. Mine Safety Disclosures	27

Item 5. Other Information	27

Item 6. Exhibits	27

SIGNATURES	28

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Balance Sheets

(in thousands, except par value and share amounts)

	June 30,			December 31,
	2021			2020
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	45,888		$	21,221
Accounts receivable, net		8,596			5,834
Inventory, net		5,481			6,013
Prepaid expenses and other current assets		5,201			3,388
Total current assets		65,166			36,456
Goodwill		20,123			20,123
Intangible assets, net		14,097			14,873
Right-of-use lease assets		419			536
Property and equipment, net		163			215
Restricted cash		40			40
Total assets	$	100,008		$	72,243

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	1,846		$	2,762
Accrued expenses		12,175			6,494
Accrued payroll and related expenses		1,912			2,878
Lease liabilities, current portion		168			204
Total current liabilities		16,101			12,338
Deferred royalty obligation, net		124,470			124,437
Accrued interest expense on deferred royalty obligation, less current portion		22,136			19,111
Lease liabilities, less current portion		251			332
Other noncurrent liabilities		4,493			4,112
Total liabilities		167,451			160,330
Commitments and contingencies (Note 6)
Shareholders’ deficit:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		3			3
Series C-1² Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020		3,906			3,906
Additional paid-in capital		987,249			984,756
Accumulated deficit		(1,058,601	)		(1,076,752	)
Total shareholders’ deficit		(67,443	)		(88,087	)
Total liabilities and shareholders’ deficit	$	100,008		$	72,243

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Revenue
Net product sales	$	11,059		$	5,805		$	19,696		$	13,396
License revenue		5,000			-			30,500			-
Total revenue		16,059			5,805			50,196			13,396
Operating expenses
Cost of product sales		2,156			808			4,887			1,524
Cost of license revenue		-			-			3,600			-
Selling, general and administrative		8,996			8,677			17,751			16,829
Research and development		1,114			8,781			2,672			17,964
Total operating expenses		12,266			18,266			28,910			36,317
Income (loss) from operations		3,793			(12,461	)		21,286			(22,921	)
Other (expense) income
Interest expense		(2,672	)		(2,470	)		(5,281	)		(4,876	)
Interest income		-			32			2			222
Other income—related party		2,532			-			2,532			4,085
Other income (expense)		80			(693	)		(370	)		(693	)
Total other (expense) income, net		(60	)		(3,131	)		(3,117	)		(1,262	)
Income (loss) before income taxes		3,733			(15,592	)		18,169			(24,183	)
Provision for income taxes		-			-			18			-
Net income (loss)	$	3,733		$	(15,592	)	$	18,151		$	(24,183	)
Earnings (loss) per share
Basic	$	0.14		$	(0.57	)	$	0.66		$	(0.89	)
Diluted	$	0.11		$	(0.57	)	$	0.53		$	(0.89	)
Shares used in computing earnings (loss) per share
Basic		27,461			27,326			27,444			27,282
Diluted		34,201			27,326			34,192			27,282

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Shareholders’ Deficit

(Unaudited)

(in thousands)

	Series C-1² Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders’ (Deficit)
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2020		4	$	3,906		27,403	$	3	$	984,756	$	(1,076,752	)	$	(88,087	)
Share-based compensation expense		-		-		-		-		1,116		-			1,116
Issuance of common stock under 2013 Equity Plan		-		-		29		-		154		-			154
Issuance of common stock under ESPP		-		-		17		-		81		-			81
Net income		-		-		-		-		-		14,418			14,418
Balance at March 31, 2021		4	$	3,906		27,449	$	3	$	986,107	$	(1,062,334	)	$	(72,318	)
Share-based compensation expense		-		-		-		-		1,024		-			1,024
Issuance of common stock under 2013 Equity Plan		-		-		-		-		1		-			1
Issuance of common stock under ESPP		-		-		33		-		117		-			117
Net income		-		-		-		-				3,733			3,733
Balance at June 30, 2021		4	$	3,906		27,482	$	3	$	987,249	$	(1,058,601	)	$	(67,443	)

	Series C-1² Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders’ (Deficit)
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2019		4	$	3,906		27,195	$	3	$	977,432	$	(1,037,331	)	$	(55,990	)
Share-based compensation expense		-		-		-		-		2,407		-			2,407
Issuance of common stock under 2013 Equity Plan		-		-		44		-		305		-			305
Issuance of common stock under ESPP		-		-		38		-		200		-			200
Net loss		-		-		-		-		-		(8,591	)		(8,591	)
Balance at March 31, 2020		4	$	3,906		27,277	$	3	$	980,344	$	(1,045,922	)	$	(61,669	)
Share-based compensation expense		-		-		-		-		1,590		-			1,590
Issuance of common stock under 2013 Equity Plan		-		-		50		-		300		-			300
Issuance of common stock under ESPP		-		-		32		-		159		-			159
Net loss		-		-		-		-		-		(15,592	)		(15,592	)
Balance at June 30, 2020		4	$	3,906		27,359	$	3	$	982,393	$	(1,061,514	)	$	(75,212	)

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Six Months Ended
	June 30,
	2021			2020
Operating activities
Net income (loss)	$	18,151		$	(24,183	)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Share-based compensation expense		2,140			3,997
Depreciation expense		56			1,798
Non-cash interest expense		3,718			3,392
Inventory fair value step-up adjustment included in cost of product sales		850			-
Amortization of intangible assets		776			-
Loss on change in fair value of contingent value rights		370			-
Amortization of right-of-use lease assets		117			699
Loss on disposal of property and equipment		-			904
Unrealized gains on short-term investments		-			(63	)
Changes in operating assets and liabilities:
Accounts receivable, net		(2,762	)		1,117
Inventory, net		(318	)		(909	)
Prepaid expenses and other current assets		(1,813	)		1,675
Accounts payable		(920	)		(1,696	)
Accrued expenses		5,032			(3,378	)
Accrued payroll and related expenses		(966	)		(2,591	)
Lease liabilities		(117	)		(1,357	)
Net cash provided by (used for) operating activities		24,314			(20,595	)
Investing activities
Proceeds from the sale of property and equipment		-			2,860
Purchases of short-term investments		-			(2,999	)
Net cash used for investing activities		-			(139	)
Financing activities
Net proceeds from issuance of common stock under 2013 Equity Plan		155			605
Net proceeds from issuance of common stock under ESPP		198			359
Net cash provided by financing activities		353			964
Net increase (decrease) in cash, cash equivalents and restricted cash		24,667			(19,770	)
Cash, cash equivalents and restricted cash, beginning of period		21,261			88,729
Cash, cash equivalents and restricted cash, end of period	$	45,928		$	68,959
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	45,888		$	68,353
Restricted cash		40			606
Total cash, cash equivalents and restricted cash	$	45,928		$	68,959

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1. Business

La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA^™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA^™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. The Company’s consolidated financial results exclude Tetraphase’s financial results prior to the acquisition closing date of July 28, 2020 (see Note 11).

In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA.

As of June 30, 2021 and December 31, 2020, the Company had cash and cash equivalents of $45.9 million and $21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K.

Summary of Significant Accounting Policies

During the six months ended June 30, 2021, other than the license revenue recognition policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.

During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales:

	U.S. Net Product Sales						Accounts Receivable
	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021			As of June 30, 2021
Customer A		34	%		36	%		37	%
Customer B		35	%		34	%		48	%
Customer C		27	%		26	%		12	%
Total		96	%		96	%		97	%

Business Combinations

The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized.

The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Goodwill

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized.

The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Revenue Recognition

Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations.

Product Sales

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

•

Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.

•

Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.

The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.

License Revenue

We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones.

If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.

At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs.

For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations.

3. Earnings (Loss) per Share

Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings (loss) per share when their effect is anti-dilutive. For the three months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 5,000 stock options. For the six months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 13,000 stock options. For the three and six months ended June 30, 2021 and 2020, there were 4.1 million and 10.2 million, respectively, of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.

4. Balance Sheet Details

Restricted Cash

Restricted cash as of June 30, 2021 and December 31, 2020 consisted of a $40,000 security deposit for the Company’s corporate purchasing credit card.

Inventory, Net

Inventory, net consisted of the following (in thousands):

	June 30,		December 31,
	2021		2020
Raw materials	$	802	$	802
Work-in-process		3,636		3,213
Finished goods		1,043		1,998
Total inventory, net	$	5,481	$	6,013

As of June 30, 2021 and December 31, 2020, inventory, net included zero and $0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note 11). As of June 30, 2021 and December 31, 2020, total inventory is recorded net of inventory reserves of $1.2 million and $0.9 million, respectively.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30,		December 31,
	2021		2020
Refundable withholding tax	$	3,375	$	-
Prepaid manufacturing costs		491		930
Prepaid clinical costs		265		820
Prepaid insurance		263		505
Other prepaid expenses and current assets		807		1,133
Total prepaid expenses and other current assets	$	5,201	$	3,388

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30,			December 31,
	2021			2020
Furniture and fixtures	$	313		$	309
Computer hardware		310			310
Software		203			733
Total property and equipment, gross		826			1,352
Accumulated depreciation and amortization		(663	)		(1,137	)
Total property and equipment, net	$	163		$	215

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	Useful Life	June 30,			December 31,
	(years)	2021			2020
Technology	10	$	14,000		$	14,000
Trade name	10		1,520			1,520
Total intangible assets, gross			15,520			15,520
Accumulated amortization			(1,423	)		(647	)
Total intangible assets, net		$	14,097		$	14,873

The intangible assets were recorded in connection with the acquisition of Tetraphase (see Note 11). The Company recorded amortization expense of $0.4 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The Company recorded no amortization expense for the six months ended June 30, 2020.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	June 30,		December 31,
	2021		2020
Accrued interest expense on deferred royalty obligation, current portion	$	4,227	$	3,567
Deferred revenue		3,037		188
Accrued royalties and in-license fees		1,235		685
Accrued manufacturing costs		1,469		627
Accrued professional fees		942		660
Accrued other		1,265		767
Total accrued expenses	$	12,175	$	6,494

Other Noncurrent Liabilities

Other noncurrent liabilities consisted of the following (in thousands):

	June 30,		December 31,
	2021		2020
Paycheck Protection Program loan	$	2,313	$	2,302
Fair value of contingent value rights (see Note 11)		2,180		1,810
Total other noncurrent liabilities	$	4,493	$	4,112

On April 22, 2020, Tetraphase entered into a promissory note for $2.3 million under the Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for forgiveness of the PPP Loan. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.

5. Deferred Royalty Obligation

In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.

On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million, net of issuance costs of $0.7 million. For the three and six months ended June 30, 2021, the Company recognized interest expense, including amortization of the obligation discount, of $2.7 million and $5.3 million, respectively. For the three and six months ended June 30, 2020, the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and $4.9 million, respectively. The carrying value of the deferred royalty obligation as of June 30, 2021 and December 31, 2020 was $124.5 million and $124.4 million, respectively, net of unamortized obligation discount of $0.5 million and $0.6 million, respectively, and was classified as a noncurrent liability. The related accrued interest expense as of June 30, 2021 and December 31, 2020 was $26.4 million and $22.7 million, respectively, of which $22.1 million and $19.1 million was classified as noncurrent liabilities, respectively. During the three and six months ended June 30, 2021, the Company made royalty payments to HCR of $0.7 million and $1.6 million, respectively. As of June 30, 2021 and December 31, 2020, the Company recorded royalty obligations payable of $0.9 million and $0.9 million, respectively, in accrued expenses. The deferred royalty obligation is classified as Level 3 in the FASB ASC Topic 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value.

Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of June 30, 2021 and December 31, 2020. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

6. Commitments and Contingencies

Lease Commitments

Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands):

2021	$	108
2022		181
2023		166
Thereafter		-
Total future minimum lease payments		455
Less: discount		36
Total lease liabilities	$	419

Lease expense under current leases was approximately $0.1 million and $0.2 million for the three and six months ended June 30, 2021, respectively. Lease expense under former leases was approximately $0.7 million and $1.4 million for the three and six months ended June 30, 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities was $51,000 and $0.1 million for the three and six months ended June 30, 2021, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.0 and $1.9 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.3 years and 3.5%, respectively.

Waltham Sublease

In December 2020, the Company entered into a sublease agreement for office space in Waltham, Massachusetts (the “Waltham Sublease”). The Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2023. In addition to rent of approximately $15,000 per month, the Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The Waltham Sublease contains customary default provisions, representations, warranties and covenants. The Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the consolidated statements of operations and records a lease liability and right-of-use asset for this lease.

San Diego Sublease

In September 2020, the Company entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $28,000 and $67,000 under the San Diego Sublease during the three and six months ended June 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for this lease.

Contingencies

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

7. Shareholders’ Equity

Preferred Stock

As of June 30, 2021 and December 31, 2020, 3,906 shares of Series C-1² Convertible Preferred Stock (“Series C-1²Preferred”) were issued, outstanding and convertible into 6,735,378 shares of common stock. As of June 30, 2021 and December 31, 2020, the Series C-1² Preferred liquidation preference was approximately $3.9 million. The Series C-1² Preferred does not pay a dividend. The holders of the Series C-1² Preferred do not have voting rights, other than for general protective rights required by the California General Corporation Law.

8. Equity Incentive Plans

2013 Equity Incentive Plan

A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2021 and December 31, 2020, 5,514,933 shares of common stock and 5,478,334 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan.

2018 Employee Stock Purchase Plan

A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2021 and December 31, 2020, 405,564 shares of common stock and 455,768 shares of common stock, respectively, remained available for future grants under the ESPP.

Equity Awards

The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows:

	Equity Awards			Weighted- average Exercise Price per Share		Weighted- average Remaining Contractual Term⁽¹⁾ (years)		Aggregate Intrinsic Value⁽²⁾ (millions)
Outstanding at December 31, 2020		4,121,666		$	8.67
Granted		562,329		$	4.96
Exercised		(29,379	)	$	5.23
Cancelled/forfeited		(569,549	)	$	9.21
Outstanding at June 30, 2021		4,085,067		$	8.10		8.3	$	0.2
Exercisable at June 30, 2021		1,107,878		$	16.71		5.7	$	-

⁽¹⁾Represents the weighted-average remaining contractual term of stock options.

⁽²⁾ Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

Share-based Compensation Expense

The classification of share-based compensation expense is summarized as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Selling, general and administrative	$	977	$	626	$	1,817	$	1,470
Research and development		47		964		323		2,527
Total share-based compensation expense	$	1,024	$	1,590	$	2,140	$	3,997

As of June 30, 2021, total unrecognized share-based compensation expense related to unvested equity awards was $8.9 million, which is expected to be recognized over a weighted-average period of 3.0 years. As of June 30, 2021, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

9. Other Income—Related Party

The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the three and six months ended June 30, 2021, the Company received distributions of $2.5 million in connection with this profits interest. During the three and six months ended June 30, 2020, the Company received distributions of zero and $4.1 million, respectively, in connection with this profits interest.

10. License Agreements

In-license Agreements

George Washington University

In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three and six months ended June 30, 2021, the Company made payments to GW of $0.4 million and $3.2 million, respectively. During the three and six months ended June 30, 2020, the Company made payments to GW of $0.5 million and $0.9 million, respectively.

Harvard University

In August 2006, the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments for the following: (i) up to approximately $15.1 million upon the achievement of certain clinical development and regulatory milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to a maximum royalty of 7.5% based on the achievement of annual net product sales thresholds; and (iv) 20% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. During the three and six months ended June 30, 2021, the Company made payments to Harvard of $1.5 million and $1.6 million, respectively, none of which related to clinical development and regulatory milestones.

Paratek Pharmaceuticals, Inc.

In March 2019, the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During the three and six months ended June 30, 2021, the Company paid $40,000 and $0.1 million, respectively, of royalties to Paratek.

Out-license Agreements

PAION AG

On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

On July 13, 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost.

Everest Medicines Limited

In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China National Medical Products Administration (“NMPA”) for XERAVA for the treatment of cIAI in patients in China. Amounts due under the Harvard License for this milestone payment were included as research and development expense on the consolidated statements of operations.

In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license revenue during the three and six months ended June 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to June 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the performance obligation to deliver XERAVA has not yet been satisfied.

11. Acquisition of Tetraphase Pharmaceuticals, Inc.

On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla.

The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. The estimated fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value.

The Purchase Price is comprised of the upfront cash of $43 million and the estimated fair value of potential future cash payments pursuant to the CVRs. The estimated fair value of assets acquired was $54.7 million, and the estimated fair value of liabilities assumed was $9.1 million.

The Purchase Price allocation as of the acquisition date is presented as follows (in thousands):

	July 28,
	2020
Cash	$	42,990
Fair Value of CVRs		2,610
Total Purchase Price	$	45,600

Cash and cash equivalents	$	8,778
Accounts receivable		1,187
Inventory		4,767
Prepaid expenses and other current assets		1,218
Property and equipment		58
Right-of-use lease assets		2,302
Restricted cash		699
Identifiable intangible assets		15,520
Goodwill		20,123
Accounts payable		(1,400	)
Accrued expenses		(2,979	)
Lease liabilities, current portion		(967	)
Lease liabilities, less current portion		(1,420	)
Other noncurrent liabilities		(2,286	)
Total Purchase Price	$	45,600

The estimated fair value of potential future cash payments pursuant to the CVRs was based on a Monte Carlo simulation and is classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy.

CVRs are measured at fair value on a recurring basis. During the three and six months ended June 30, 2021, the Company recorded a $0.1 million gain and $0.4 million loss, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs.

The Company recorded a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost, adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from the viewpoint of a market participant. This fair value step-up adjustment is recorded as cost of product sales when the inventory is sold to customers, zero and $0.9 million of which was included in cost of product sales during the three and six months ended June 30, 2021, respectively.

Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years.

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company did not make a Section 338 election.

12. Company-wide Realignments

On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of June 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment.

In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of June 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount.

13. Income Taxes

For the three and six months ended June 30, 2021, the Company recorded a provision for income taxes of zero and $18,000, respectively. For the three and six months ended June 30, 2020, the Company did not record a provision for income taxes. As of June 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were no unrecognized tax benefits as of June 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and the related notes and other financial information included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 8, 2021 (the “Form 10-K”).

Forward-looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, future expenses, financing needs, plans or intentions relating to acquisitions, business trends and other information referred to under this section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors are described under “Risk Factors” in Item 1A of our Form 10-K for the year ended December 31, 2020. We caution you that these risks, uncertainties and other factors may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will affect us or our business in the way expected. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

Business Overview

La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA^™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA^™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. La Jolla’s consolidated financial results exclude Tetraphase’s financial results prior to the acquisition closing date of July 28, 2020.

Product Portfolio

⁽¹⁾ For U.S. and European approval

⁽²⁾ U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock

European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies

⁽³⁾ U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of cIAIs in patients 18 years of age and older

European Union: XERAVA is indicated for the treatment of cIAI in adults

GIAPREZA^™ (angiotensin II)

GIAPREZA^™ (angiotensin II) injection is approved by the FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (“EC”) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (“RAAS”), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and is marketed in Europe by PAION Deutschland GmbH on behalf of La Jolla Pharma, LLC.

XERAVA^™ (eravacycline)

XERAVA^™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older. XERAVA is approved by the EC for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and is marketed in Europe by PAION Deutschland GmbH on behalf of Tetraphase. Everest, the Company’s licensee for mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines, recently submitted an NDA in China, which was accepted by the China National Medical Products Administration (“NMPA”) in March 2021.

Product Candidates

In connection with the acquisition of Tetraphase, we acquired the following product candidates that are in early stage clinical development: (1) TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; (2) TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and (3) TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. At this time, there are no active studies nor anticipated future studies for any of these product candidates. We intend to seek out-license opportunities for these product candidates; however, at this time, we are unable to predict the likelihood of successfully out-licensing any of these product candidates.

Components of Our Results of Operations

The following table summarizes our results of operations for each of the periods below (in thousands):

	Three Months Ended									Six Months Ended
	June 30,									June 30,
	2021			2020			Change			2021			2020			Change
Net product sales	$	11,059		$	5,805		$	5,254		$	19,696		$	13,396		$	6,300
License revenue		5,000			-			5,000			30,500			-			30,500
Cost of product sales		2,156			808			1,348			4,887			1,524			3,363
Cost of license revenue		-			-			-			3,600			-			3,600
Selling, general and administrative expense		8,996			8,677			319			17,751			16,829			922
Research and development expense		1,114			8,781			(7,667	)		2,672			17,964			(15,292	)
Other (expense) income, net		(60	)		(3,131	)		3,071			(3,117	)		(1,262	)		(1,855	)
Provision for income taxes		-			-			-			18			-			18
Net income (loss)	$	3,733		$	(15,592	)	$	19,325		$	18,151		$	(24,183	)	$	42,334

La Jolla’s consolidated financial results for the three and six months ended June 30, 2020 exclude the financial results of Tetraphase. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020.

Net Product Sales

Net product sales consist of revenue recognized from sales of GIAPREZA and XERAVA to hospitals and other healthcare organizations in the U.S. through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes.

La Jolla’s net product sales were $11.1 million and $19.7 million for the three and six months ended June 30, 2021, respectively, compared to $5.8 million and $13.4 million, respectively, for the same periods in 2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales excludes XERAVA for the three and six months ended June 30, 2020.

GIAPREZA U.S. net sales were $8.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, compared to $5.8 million and $13.4 million for the same periods in 2020. GIAPREZA U.S. net sales increased during the three and six months ended June 30, 2021 compared to the same periods in 2020 due to an increase in the number of vials sold to our customers. XERAVA U.S. net sales were $2.5 million and $4.3 million for the three and six months ended June 30, 2021, compared to zero for the same periods in 2020.

License Revenue

License revenue consists of revenue from out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development, regulatory or commercial milestone payments; and/or (iii) sales-based royalties. License revenue also consists of revenue from commercial supply agreements with our out-licensees to supply a minimum quantity of our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases.

License revenue was $5.0 million for the three months ended June 30, 2021, which consists of the transfer of certain XERAVA-related manufacturing know-how to Everest in connection with the Everest commercial supply agreement. License revenue was $30.5 million for the six months ended June 30, 2021, which consists of: (i) a $22.5 million upfront cash payment in connection with the PAION License; (ii) a $3.0 million regulatory milestone cash payment in connection with the Everest License; and (iii) $5.0 million for the transfer of certain XERAVA-related manufacturing know-how to Everest in connection with the Everest commercial supply agreement. The Company did not record license revenue during the three and six months ended June 30, 2020.

Cost of Product Sales

Cost of product sales consists primarily of expense associated with: (i) royalties payable to George Washington University, Harvard University and Paratek Pharmaceuticals, Inc.; (ii) manufacturing; (iii) the inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase; and (iv) shipping and distribution.

Cost of product sales were $2.2 million and $4.9 million for the three and six months ended June 30, 2021, respectively, compared to $0.8 million and $1.5 million, respectively, for the same periods in 2020. Cost of product sales excludes XERAVA for the three and six months ended June 30, 2020. For the three and six months ended June 30, 2021, cost of product sales includes zero and $0.9 million, respectively, of the inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase.

Cost of License Revenue

Cost of license revenue consists of amounts due under in-license agreements in connection with license revenue from commercially approved product. Cost of license revenue recognized in connection with product that is not commercially approved is recorded as research and development expense. Cost of license revenue was zero and $3.6 million for the three and six months ended June 30, 2021, respectively, which consists of amounts due under the George Washington University and Harvard University license agreements in connection with the upfront cash payment received from the PAION License. The Company did not record cost of license revenue during the three and six months ended June 30, 2020.

Selling, General and Administrative Expense

Selling, general and administrative expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) professional fees for legal, patent, consulting, accounting and audit services; (ii) sales and marketing costs such as speaker programs, advertising and promotion; and (iii) facilities and information technology. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in sales, finance and administrative functions. We do not expect our selling, general and administrative expense to change significantly in the near term.

The following table summarizes these expenses for each of the periods below (in thousands):

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2021		2020		Change			2021		2020		Change
Non-personnel expense:
Sales and marketing	$	1,315	$	588	$	727		$	2,510	$	1,811	$	699
Professional fees		1,266		1,356		(90	)		2,794		2,227		567
Facility		105		554		(449	)		119		1,047		(928	)
Other		811		339		472			1,603		925		678
Total non-personnel expense		3,497		2,837		660			7,026		6,010		1,016
Personnel expense:
Salaries, bonuses and benefits		4,522		3,261		1,261			8,908		7,396		1,512
One-time charges for reductions in headcount		-		1,953		(1,953	)		-		1,953		(1,953	)
Share-based compensation expense		977		626		351			1,817		1,470		347
Total personnel expense		5,499		5,840		(341	)		10,725		10,819		(94	)
Total selling, general and administrative expense	$	8,996	$	8,677	$	319		$	17,751	$	16,829	$	922

During the three and six months ended June 30, 2021, total selling, general and administrative non-personnel expense increased compared to the same period in 2020 primarily resulting from the inclusion of Tetraphase-related costs, which are excluded from La Jolla’s financial results for the three and six months ended June 30, 2020.

During the three and six months ended June 30, 2021, total selling, general and administrative personnel expense decreased compared to the same periods in 2020 primarily as a result of one-time charges in 2020 resulting from a reduction of headcount from a Company-wide realignment in May 2020; partially offset by an increase in headcount resulting from the acquisition of Tetraphase.

Research and Development Expense

Research and development expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) amounts due under in-license agreements for drug product that is not commercially approved; (ii) manufacturing development; (iii) facilities and information technology; and (iv) conducting clinical studies. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in research and development functions. We expect our research and development expense to decrease in the near term.

The following table summarizes these expenses for each of the periods below (in thousands):

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2021		2020		Change			2021		2020		Change
Non-personnel expense:
GIAPREZA	$	304	$	1,762	$	(1,458	)	$	479	$	2,843	$	(2,364	)
XERAVA		154		-		154			416		-		416
LJPC-401		72		-		72			102		1,531		(1,429	)
LJPC-0118		11		404		(393	)		16		917		(901	)
Facility		2		1,124		(1,122	)		5		2,560		(2,555	)
Other		153		149		4			726		673		53
Total non-personnel expense		696		3,439		(2,743	)		1,744		8,524		(6,780	)
Personnel expense:
Salaries, bonuses and benefits		371		1,933		(1,562	)		605		4,468		(3,863	)
One-time charges for reductions in headcount		-		2,445		(2,445	)		-		2,445		(2,445	)
Share-based compensation expense		47		964		(917	)		323		2,527		(2,204	)
Total personnel expense		418		5,342		(4,924	)		928		9,440		(8,512	)
Total research and development expense	$	1,114	$	8,781	$	(7,667	)	$	2,672	$	17,964	$	(15,292	)

During the three and six months ended June 30, 2021, total research and development non-personnel expense decreased compared to the same periods in 2020 primarily as a result of: (i) decreases in program-related expenses as we de-prioritized our product candidates and focused on the commercialization of GIAPREZA and XERAVA; (ii) decreases in manufacturing development-related expenses for GIAPREZA; and (iii) decreases in facility-related expenses primarily as a result of the termination of our lease for office and laboratory space in San Diego, California effective August 31, 2020; partially offset by increases in manufacturing and clinical development costs related to the acquisition of XERAVA.

During the three and six months ended June 30, 2021, total research and development personnel expense, including share-based compensation expense, decreased compared to the same periods in 2020 as a result of: (i) reduced headcount; (ii) one-time charges in 2020 resulting from a reduction of headcount from a Company-wide realignment in May 2020; and (iii) a decrease in personnel allocations to research and development activities in 2021.

Tetraphase’s research and development expense is excluded from La Jolla’s financial results for the three and six months ended June 30, 2020.

Other (Expense) Income, Net

Other (expense) income, net consists of the following: (i) interest expense accrued for our deferred royalty obligation; (ii) income from distributions received in connection with our non-voting profits interest in a related party; (iii) gain (loss) from changes in the fair value of contingent value rights (“CVRs”); and (iv) interest income generated from cash held in savings accounts.

During the three months ended June 30, 2021, other (expense) income, net was $(0.1) million, compared to $(3.1) million for the same period in 2020. This $3.0 million increase in other (expense) income, net was primarily due to: (i) a $2.5 million increase in the receipt of distributions in connection with the Company’s non-voting profits interest in a related party; and (ii) a $0.9 million decrease in loss on disposal of equipment; partially offset by a $0.2 million increase in interest expense for our deferred royalty obligation.

During the six months ended June 30, 2021, other (expense) income, net was $(3.1) million, compared to $(1.3) million for the same period in 2020. This $1.8 million decrease in other (expense) income, net was primarily due to: (i) a $1.6 million decrease in the receipt of distributions in connection with the Company’s non-voting profits interest in a related party; (ii) a $0.4 million decrease in loss from changes in the fair value of CVRs; (iii) a $0.4 million increase in interest expense for our deferred royalty obligation; and (iv) a $0.2 million decrease in interest income generated from cash held in savings accounts; partially offset by a $0.9 million decrease in loss on disposal of equipment.

Liquidity and Capital Resources

As of June 30, 2021 and December 31, 2020, we had cash and cash equivalents of $45.9 million and $21.2 million, respectively. Based on our current operating plans and projections, we believe that our existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. The Company expects to fund future operations with existing cash or cash generated from operations.

La Jolla’s net cash provided by (used for) operating activities for the three and six months ended June 30, 2021 was $7.1 million and $24.3 million, respectively, compared to $(8.4) million and $(20.6) million, respectively, for the same periods in 2020. Net cash provided by (used for) operating activities for the three and six months ended June 30, 2021, excluding net receipts in connection with out-license agreements, commercial supply agreements and payments related to reductions in headcount, was $2.2 million and $0.4 million, respectively, compared to $(6.7) million and $(16.0) million, respectively, for the same periods in 2020. Net receipts (payments) in connection with out-license agreements were $(1.4) million and $18.4 million for the three and six months ended June 30, 2021,respectively, and zero for the same periods in 2020. Net receipts in connection with commercial supply agreements were $6.8 million for the three and six months ended June 30, 2021, and zero for the same periods in 2020. Payments related to reductions in headcount were $0.5 million and $1.3 million for the three and six months ended June 30, 2021, respectively, and $1.6 million and $4.6 million, respectively, for the same periods in 2020.

The amount and timing of additional future funding needs, if any, will depend on many factors, including the success of our commercialization efforts for GIAPREZA and XERAVA and our ability to control expenses. If necessary, we will raise additional capital through equity or debt financings. We can provide no assurance that additional financing will be available to us on favorable terms, or at all.

Contractual Obligations

HealthCare Royalty Partners Royalty Agreement

In May 2018, we closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, we received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by our wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.

In-license Agreements

George Washington University

2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA.

Harvard University

Paratek Pharmaceuticals, Inc.

Out-license Agreements

PAION AG

On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement with PAION AG and its wholly owned subsidiary (collectively, “PAION”) (the “PAION License”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

Everest Medicines Limited

containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China NMPA for XERAVA for the treatment of cIAI in patients in China.

Off−Balance Sheet Arrangements

We have no off−balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in our financial condition, expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Estimates

We believe the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of our Form 10-K for the year ended December 31, 2020 are most critical to understanding and evaluating our reported financial results. During the six months ended June 30, 2021, other than the license revenue recognition policy described in Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q, there have been no material changes to the critical accounting policies and estimates as described in Item 7 of our Form 10-K for the year ended December 31, 2020.

Recent Accounting Pronouncements

See Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of June 30, 2021, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to claims and litigation arising in the ordinary course of business. We are not a party to any material legal proceedings, nor are we aware of any material pending or threatened litigation.

Item 1A. Risk Factors

Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit No.		Exhibit Description

3.1		Amended and Restated Articles of Incorporation of La Jolla Pharmaceutical Company (incorporated herein by reference to Exhibit 4.1 to the Company’s Form S-8, as filed with the SEC on December 20, 2013)

3.2		La Jolla Pharmaceutical Company Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.4 to the Company’s Form S-8-A12B/A, as filed with the SEC on October 17, 2014)

31.1		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			La Jolla Pharmaceutical Company

Date:	August 5, 2021	By:	/s/ Larry Edwards
			Larry Edwards
			Director, President and Chief Executive Officer
			(principal executive officer)

			/s/ Michael Hearne
			Michael Hearne
			Chief Financial Officer
			(principal financial and accounting officer)

EX-31.1 2 ljpc-ex311_6.htm EX-31.1 ljpc-ex311_6.htm

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, Larry Edwards, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of La Jolla Pharmaceutical Company;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 5, 2021	By:	/s/ Larry Edwards
		Larry Edwards
		Director, President and Chief Executive Officer (principal executive officer)

EX-31.2 3 ljpc-ex312_7.htm EX-31.2 ljpc-ex312_7.htm

EXHIBIT 31.2

SECTION 302 CERTIFICATION

I, Michael Hearne, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of La Jolla Pharmaceutical Company;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 5, 2021	By:	/s/ Michael Hearne
		Michael Hearne
		Chief Financial Officer (principal financial and accounting officer)

EX-32.1 4 ljpc-ex321_8.htm EX-32.1 ljpc-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of La Jolla Pharmaceutical Company (the “Company”) for the quarter ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 5, 2021


/s/ Larry Edwards
Larry Edwards
Director, President and Chief Executive Officer (principal executive officer)

/s/ Michael Hearne
Michael Hearne
Chief Financial Officer (principal financial and accounting officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Note: A signed original of this written statement required by Section 906 has been provided to La Jolla Pharmaceutical Company and will be retained by La Jolla Pharmaceutical Company and furnished to the Securities and Exchange Commission or its staff upon request.

GRAPHIC 5 g4vfo5s522gp000001.jpg GRAPHIC begin 644 g4vfo5s522gp000001.jpg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end EX-101.SCH 6 ljpc-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Earnings (Loss) per Share link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Deferred Royalty Obligation link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Shareholders Equity link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Equity Incentive Plans link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Other Income—Related Party link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Company-wide Realignment link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Equity Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Earnings (Loss) per Share - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Balance Sheet Details - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Details - Property Plant and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Balance Sheet Details - Schedule of Intangible Assets, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Balance Sheet Details - Summary of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Deferred Royalty Obligation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)2 link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Shareholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Equity Incentive Plans - Narrative (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Equity Incentive Plans - Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Equity Incentive Plans - Share-based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Other Income-Related Party - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - License Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Company-wide Realignments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 ljpc-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ljpc-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ljpc-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lessee operating lease liability payments excluding lease operating costs due remainder of fiscal year. Lessee operating lease liability payments excluding lease operating costs due next twelve months. Lessee operating lease liability payments excluding lease operating costs due year two. Lessee operating lease liability payments excluding lease operating costs due thereafter. Lessee operating lease liability payments excluding lease operating cost, undiscounted excess amount. Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Central Index Key Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Deferred Royalty Obligations Accrued interest expense on deferred royalty obligation, less current portion. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series C One Convertible Preferred Stock [Member] Series C-1 Convertible Preferred Stock Series C One Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable, net Accounts Receivable Net Current Inventory, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Goodwill Goodwill Intangible assets, net Intangible Assets Net Excluding Goodwill Right-of-use lease assets Operating Lease Right Of Use Asset Property and equipment, net Property Plant And Equipment Net Restricted cash Restricted Cash Noncurrent Total assets Assets LIABILITIES AND SHAREHOLDERS’ DEFICIT Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Accrued payroll and related expenses Employee Related Liabilities Current Lease liabilities, current portion Operating Lease Liability Current Total current liabilities Liabilities Current Deferred royalty obligation, net Deferred Royalty Obligations Accrued interest expense on deferred royalty obligation, less current portion Accrued Interest Expense On Deferred Royalty Obligation Less Current Portion Lease liabilities, less current portion Operating Lease Liability Noncurrent Other noncurrent liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 6) Commitments And Contingencies Shareholders’ deficit: Stockholders Equity [Abstract] Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively Common Stock Value Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020 Preferred Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ deficit Stockholders Equity Total liabilities and shareholders’ deficit Liabilities And Stockholders Equity Common stock, par value (USD per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares issued (in shares) Common Stock Shares Issued Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Preferred stock, par value (USD per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Preferred stock, liquidation Temporary Equity Liquidation Preference Income Statement [Abstract] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Product Sales Product [Member] License Revenue License [Member] Revenue Revenues [Abstract] Revenue Revenue From Contract With Customer Including Assessed Tax Total revenue Revenues Operating expenses Costs And Expenses [Abstract] Cost of product sales, license revenue Cost Of Goods And Services Sold Selling, general and administrative Selling General And Administrative Expense Research and development Research And Development Expense Total operating expenses Costs And Expenses Income (loss) from operations Operating Income Loss Other (expense) income Interest Income Expense Net [Abstract] Interest expense Interest Expense Other Interest income Interest Income Other Other income—related party Related Party Transaction Other Revenues From Transactions With Related Party Other income (expense) Other Nonoperating Income Expense Total other (expense) income, net Interest Income Expense Net Income (loss) before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net income (loss) Net Income Loss Earnings (loss) per share Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Shares used in computing earnings (loss) per share Earnings Per Share Basic And Diluted Other Disclosures [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase Decrease In Stockholders Equity Roll Forward Beginning Balance Beginning Balance (in shares) Shares Outstanding Share-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Issuance of common stock under 2013 Equity Plan Stock Issued During Period Value Stock Options Exercised Issuance of common stock under 2013 Equity Plan (in shares) Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under ESPP Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock under ESPP (in shares) Stock Issued During Period Shares Employee Stock Purchase Plans Net income (loss) Ending Balance Ending Balance (in shares) Non-Cash Interest Expense Loss on change in fair value of contingent value rights. Amortization of right-of-use lease assets. Unrealized Gains On Short-Term Investments Increase (Decrease) Operating Lease, Liability Proceeds From Issuance Of Common Stock From Employee Share Purchase Program Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Share-based compensation expense Share Based Compensation Depreciation expense Depreciation Non-cash interest expense Non Cash Interest Expense Inventory fair value step-up adjustment included in cost of product sales Inventory Write Down Amortization of intangible assets Amortization Of Intangible Assets Loss on change in fair value of contingent value rights Loss On Change In Fair Value Of Contingent Value Rights Amortization of right-of-use lease assets Amortization Of Right Of Use Lease Assets Loss on disposal of property and equipment Gain Loss On Disposition Of Assets1 Unrealized gains on short-term investments Unrealized Gains On Short Term Investments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Inventory, net Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable And Accrued Liabilities Accrued expenses Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued payroll and related expenses Increase Decrease In Employee Related Liabilities Lease liabilities Increase Decrease Operating Lease Liability Net cash provided by (used for) operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Proceeds from the sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Purchases of short-term investments Payments To Acquire Short Term Investments Net cash used for investing activities Net Cash Provided By Used In Investing Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Net proceeds from issuance of common stock under 2013 Equity Plan Proceeds From Issuance Of Common Stock Net proceeds from issuance of common stock under ESPP Proceeds From Issuance Of Common Stock From Employee Share Purchase Program Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets Cash Cash Equivalents And Short Term Investments [Abstract] Restricted cash Restricted Cash Organization Consolidation And Presentation Of Financial Statements [Abstract] Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Earnings (Loss) per Share Earnings Per Share [Text Block] Balance Sheet Account Details Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Deferred Royalty Obligation Debt Disclosure [Text Block] Leases [Abstract] Commitments and Contingencies Lessee Operating Leases [Text Block] Equity [Abstract] Shareholders Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Incentive Plans Compensation And Employee Benefit Plans [Text Block] Related Party Transactions [Abstract] Other Income—Related Party Related Party Transactions Disclosure [Text Block] Licensed Technology Agreement [Text Block] Research And Development [Abstract] License Agreements Licensed Technology Agreement [Text Block] Business Combinations [Abstract] Acquisition of Tetraphase Pharmaceuticals, Inc Business Combination Disclosure [Text Block] Restructuring And Related Activities [Abstract] Company-wide Realignments Restructuring And Related Activities Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Concentration of Credit Risk Concentration Risk Credit Risk Business Combinations Business Combinations Policy Intangible Assets Goodwill And Intangible Assets Intangible Assets Policy Goodwill Goodwill And Intangible Assets Goodwill Policy Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of Concentration Risk Schedules Of Concentration Of Risk By Risk Factor [Text Block] Schedule of Inventory Schedule Of Inventory Current Table [Text Block] Schedule of prepaid expenses and other current asset. Schedule of Prepaid Expenses and Other Current Assets Schedule Of Prepaid Expenses And Other Current Asset Table [Text Block] Property, Plant and Equipment Property Plant And Equipment [Text Block] Schedule of Intangible Assets, Net Schedule Of Finite Lived Intangible Assets Table [Text Block] Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of Other Noncurrent Liabilities Other Noncurrent Liabilities Table [Text Block] Schedule of future minimum lease payments excluding operating costs. Schedule of Future Minimum Lease Payments Excluding Operating Costs Schedule Of Future Minimum Lease Payments Excluding Operating Costs Table [Text Block] Equity Award Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Share-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Purchase Price Allocation as of Acquisition Date Schedule Of Business Acquisitions By Acquisition [Text Block] Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Tetraphase Pharmaceuticals, Inc. [Member] Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals Inc [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] License Agreement License Agreement Terms [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Upfront cash for acquisition Business Combination Consideration Transferred1 Future cash payments Effect On Future Cash Flows Amount Proceeds from upfront cash payment. Commercial Milestone Payments. Percentage of refundable tax withholding. Proceeds from upfront cash payment Proceeds From Upfront Cash Payment Percentage of refundable tax withholding Percentage Of Refundable Tax Withholding Commercial milestone payments Commercial Milestone Payments Number of major customers. Number of hospitals purchased GIAPREZA. Number of hospitals and other healthcare organizations purchased XERAVA. Concentration Risk [Table] Concentration Risk [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] U.S. UNITED STATES Concentration Risk [Line Items] Concentration Risk [Line Items] Number of hospitals purchased GIAPREZA Number Of Hospitals Purchased G I A P R E Z A Number of hospitals and other healthcare organizations purchased XERAVA Number Of Hospitals And Other Healthcare Organizations Purchased X E R A V A Number of major customers Number Of Major Customers Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Customer A [Member] Customer A Customer A [Member] Customer B [Member] Customer B Customer B [Member] Customer C [Member] Customer C Customer C [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] U.S. Net Product Sales Sales Revenue Net [Member] Accounts Receivable Accounts Receivable [Member] Concentration of credit risk Concentration Risk Percentage1 Impairment of intangible assets Impairment Of Intangible Assets Excluding Goodwill Goodwill impairment charges Goodwill And Intangible Asset Impairment Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares) Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potential common shares that were included in the calculation of diluted earnings per share Weighted Average Number Diluted Shares Outstanding Adjustment Issuance of common stock up on conversion of preferred stock Incremental Common Shares Attributable To Conversion Of Preferred Stock Stock options Incremental Common Shares Attributable To Share Based Payment Arrangements Schedule Of Restricted Cash And Cash Equivalents [Table] Schedule Of Restricted Cash And Cash Equivalents [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Credit Card Credit Card [Member] Nonrecurring Adjustment Nonrecurring Adjustment [Axis] Nonrecurring Adjustment Nonrecurring Adjustment [Domain] Fair Value Step-Up Adjustment to Inventory Fair Value Adjustment To Inventory [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Restricted Cash And Cash Equivalents Items [Line Items] Restricted Cash And Cash Equivalents Items [Line Items] Raw materials Inventory Raw Materials Net Of Reserves Work-in-process Inventory Work In Process Net Of Reserves Finished goods Inventory Finished Goods Net Of Reserves Total inventory, net Inventory reserves Inventory Valuation Reserves Refundable withholding tax current. Prepaid manufacturing costs, current. Prepaid clinical costs current. Other prepaid expenses and current assets. Prepaid Expense And Other Assets [Abstract] Refundable withholding tax Refundable Withholding Tax Current Prepaid manufacturing costs Prepaid Manufacturing Costs Current Prepaid clinical costs Prepaid Clinical Costs Current Prepaid insurance Prepaid Insurance Other prepaid expenses and current assets Other Prepaid Expenses And Current Assets Total prepaid expenses and other current assets Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Furniture and Fixtures [Member] Furniture And Fixtures [Member] Computer Equipment [Member] Computer Equipment [Member] Software and Software Development Costs [Member] Software And Software Development Costs [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Total property and equipment, gross Property Plant And Equipment Gross Accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total property and equipment, net Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Technology Technology Based Intangible Assets [Member] Trade Name Trade Names [Member] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Total intangible assets, gross Finite Lived Intangible Assets Gross Accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Total intangible assets, net Finite Lived Intangible Assets Net Useful Life (years) Finite Lived Intangible Asset Useful Life Amortization expense Accrued interest expense on deferred royalty obligation, current. Accrued royalties and in-license fees current. Accrued Manufacturing Costs Accrued interest expense on deferred royalty obligation, current portion Accrued Interest Expense On Deferred Royalty Obligation Current Deferred revenue Deferred Revenue Current Accrued royalties and in-license fees Accrued Royalties And In License Fees Current Accrued manufacturing costs Accrued Manufacturing Costs Accrued professional fees Accrued Professional Fees Current Accrued other Other Accrued Liabilities Current Total accrued expenses Paycheck protection program loan noncurrent. Fair value of contingent value rights noncurrent. Other Liabilities Noncurrent [Abstract] Paycheck Protection Program loan Paycheck Protection Program Loan Noncurrent Fair value of contingent value rights (see Note 11) Fair Value Of Contingent Value Rights Noncurrent Total other noncurrent liabilities Promissory note Debt Instrument Face Amount Debt instrument, interest rate Debt Instrument Interest Rate Stated Percentage Royalty Agreement, Amount Funded Royalty Agreement, Maximum Potential Payout, Percent Royalty Agreement, Increase In Maximum Potential Payout, Percent Royalty Agreement, Required Payment For Breach Of Agreement, Payment Two Debt Instrument [Table] Debt Instrument [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] HealthCare Royalty Partners [Member] HealthCare Royalty Partners Health Care Royalty Partners [Member] Royalty Agreement, Payout Period [Axis] Royalty Agreement Payout Period Royalty Agreement Payout Period [Axis] [Domain] for Royalty Agreement, Payout Period [Axis] Royalty Agreement Payout Period Royalty Agreement Payout Period [Domain] Royalty Agreement, Payout Period One [Member] Period One Royalty Agreement Payout Period One [Member] Royalty Agreement, Payout Period Two [Member] Period Two Royalty Agreement Payout Period Two [Member] Royalty Agreement, Payout Period Three [Member] Payout Period Royalty Agreement Payout Period Three [Member] Royalty Financing Agreement [Member] Royalty Financing Agreement Royalty Financing Agreement [Member] Loans Payable Loans Payable [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Proceeds from royalty agreement Royalty Agreement Amount Funded Maximum potential royalty payout Royalty Agreement Maximum Potential Payout Percent Increase in maximum potential payout percent Royalty Agreement Increase In Maximum Potential Payout Percent Required payment for breach of agreement, payment two Royalty Agreement Required Payment For Breach Of Agreement Payment Two Royalty Obligation Payable Debt issuance costs Deferred Finance Costs Net Interest expense Interest Expense Borrowings Unamortized debt discount Debt Instrument Unamortized Discount Accrued interest expense Interest And Dividends Payable Current And Noncurrent Royalty payments Repayments Of Debt Royalty obligation payable Royalty Obligation Payable Royalty Agreement, Required Payment For Breach Of Agreement, Payment One Required payment for breach of agreement, payment one Royalty Agreement Required Payment For Breach Of Agreement Payment One Lessee operating lease liability payments excluding lease operating cost due. 2021 Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Remainder Of Fiscal Year 2022 Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Year Two Thereafter Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Thereafter Total future minimum lease payments Lessee Operating Lease Liability Payments Excluding Lease Operating Cost Due Less: discount Lessee Operating Lease Liability Payments Excluding Lease Operating Cost Undiscounted Excess Amount Total lease liabilities Operating Lease Liability Lessee Lease Description [Table] Lessee Lease Description [Table] Waltham, Massachusetts. Waltham Sublease Waltham Massachusetts [Member] San Diego California. San Diego Sublease San Diego California [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Lease expense Lease Cost Operating lease, cash payments Operating Lease Payments Operating lease weighted-average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Operating lease weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Sublease rent expense per month. Expiration date Lease Expiration Date1 Sublease rent per month Sublease Rent Expense Per Month Payments of sublease. Sublease term. Sublease cancellable written notice period. Sublease term Sublease Term Sublease cancellable written notice period Sublease Cancellable Written Notice Period Payments of sublease Payments Of Sublease Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Class Of Stock [Line Items] Class Of Stock [Line Items] Convertible Preferred Stock, Shares Reserved for Future Issuance Convertible Preferred Stock Shares Reserved For Future Issuance Preferred stock, liquidation preference Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two Thousand and Thirteen Plan [Member] 2013 Equity Plan [Member] Two Thousandand Thirteen Plan [Member] 2018 Employee Stock Purchase Plan [Member] 2018 Employee Stock Purchase Plan [Member] A2018 Employee Stock Purchase Plan [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Share-based Payment Arrangement, Option [Member] Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of shares reserved for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Shares available for grant (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Underlying Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted, Shares underlying stock options and restricted stock awards (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised, Shares underlying stock options and restricted stock awards (in shares) Cancelled/Forfeited, Shares underlying stock options and restricted stock awards (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Shares Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted- Average Exercise Price per Share Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Outstanding beginning balance, Weighted - average exercise price (usd per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted, Weighted - average exercise price (usd per share) Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised, Weighted - average exercise price (usd per share) Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Cancelled/forfeited, Weighted - average exercise price (usd per share) Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Outstanding ending balance, Weighted - average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Outstanding, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Exercisable, Aggregate Intrinsic Value Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Change of equity awards outstanding or equity awards, exercise price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Selling, General and Administrative Expenses [Member] General And Administrative Expense [Member] Research and development [Member] Research And Development Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-based compensation expense Allocated Share Based Compensation Expense Unamortized share-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Recognized weighted average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unrecognized share-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Percentage of royalty on net sales. Percentage of royalty payments on behalf of sublicensee. Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] GeorgeWashington [Member] George Washington George Washington [Member] Harvard University. Harvard Harvard University [Member] Paratek Pharmaceuticals, Incorporation. Paratek Paratek Pharmaceuticals Incorporation [Member] PAION AG. PAION AG P A I O N A G [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Everest medicines limited. Everest Medicines Limited Everest Medicines Limited [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Commercial supply agreement. Commercial Supply Agreement Commercial Supply Agreement [Member] Research And Development Arrangement Contract To Perform For Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Milestone payment Research And Development Expense Excluding Acquired In Process Cost Percentage of royalty on net sales Percentage Of Royalty On Net Sales Percentage of payments received from sublicensee Percentage Of Royalty Payments On Behalf Of Sublicensee Clinical development and regulatory milestones amount payable. Percentage of minimum royalty rate. Percentage of maximum royalty based on achievement of annual net product sales thresholds. Payments for clinical development and regulatory milestone. Clinical development and regulatory milestones amount payable Clinical Development And Regulatory Milestones Amount Payable Percentage of minimum royalty rate Percentage Of Minimum Royalty Rate Percentage of maximum royalty based on achievement of annual net product sales thresholds Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds Royalties payments Payments For Royalties Payments related to clinical development and regulatory milestones Payments For Clinical Development And Regulatory Milestone Claim expiration date. Claim expiration Claim Expiration Date Upfront Cash Payment. Supply agreement term. Upfront cash payment Upfront Cash Payment Supply agreement term Supply Agreement Term Regulatory milestone payments receivable. Sales milestone payments receivable. Additional regulatory milestone payments receivable Regulatory Milestone Payments Receivable Sales milestone payments receivable Sales Milestone Payments Receivable Royalties payable description. Royalties payable period after first commercial sale of product. Royalties payable description Royalties Payable Description Royalties payable period after first commercial sale of product Royalties Payable Period After First Commercial Sale Of Product Milestone payments received Proceeds From Collaborators Proceeds from upfront payments. Proceeds from upfront technology transfer payment. Proceeds from partial prepayment for XERAVA. Additional technology transfer payment receivable. Percentage of reimbursed for direct and certain indirect manufacturing costs. Proceeds from upfront payments Proceeds From Upfront Payments Proceeds from upfront technology transfer payment Proceeds From Upfront Technology Transfer Payment Proceeds from partial prepayment for XERAVA Proceeds From Partial Prepayment For X E R A V A Additional technology transfer payment receivable by January 30, 2022 Additional Technology Transfer Payment Receivable Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023 Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs Revenue Deferred revenue Deferred Revenue Transaction Type Transaction Type [Axis] Transaction Transaction [Domain] Agreement 1 [Member] Agreement 1 Agreement1 [Member] Agreement 2 [Member] Agreement 2 Agreement2 [Member] Agreement 3 [Member] Agreement 3 Agreement3 [Member] Cost of Product Sales Cost Of Sales [Member] Business acquisition, date of acquisition agreement Business Acquisition Date Of Acquisition Agreement1 Additional aggregate payments Business Combination Acquisition Related Costs Business acquisition, description Business Acquisition Description Of Acquired Entity Proceeds from businesses and interest in affiliates Payments For Proceeds From Businesses And Interest In Affiliates Net sales from related parties Revenue From Related Parties Estimated fair value of assets acquired Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Estimated fair value of liabilities assumed Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities Fair value of contingent value rights. Business combination recognized identifiable assets acquired and liabilities assumed right-of-use lease assets. Business combination recognized identifiable assets acquired and liabilities assumed restricted cash. Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses. Business combination recognized identifiable assets acquired and liabilities assumed lease liabilities, less current portion. Cash Fair Value of CVRs Fair Value Of Contingent Value Rights Total Purchase Price Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net Cash and cash equivalents Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Accounts receivable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables Inventory Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory Prepaid expenses and other current assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets Property and equipment Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment Right-of-use lease assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Lease Assets Restricted cash Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash Identifiable intangible assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets Accounts payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable Accrued expenses Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses Lease liabilities, current portion Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation Lease liabilities, less current portion Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Lease Liabilities Less Current Portion Other noncurrent liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other Fair value measurement with reconciliation recurring basis gain (loss) included in other income (expense). Gail (loss) recorded in other (expense) income resulting from the change in fair value of CVRs Fair Value Measurement With Reconciliation Recurring Basis Gain Loss Included In Other Income Expense Inventory fair value step up adjustment Weighted-average Years Acquired Finite Lived Intangible Assets Weighted Average Useful Life Schedule Of Restructuring And Related Costs [Table] Schedule Of Restructuring And Related Costs [Table] Tetraphase Pharmaceuticals, Inc. [Member] Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals Inc. [Member] Restructuring Cost And Reserve [Line Items] Restructuring Cost And Reserve [Line Items] Reversal of non-cash-stock-based compensation expense Employee Benefits And Share Based Compensation Noncash Restructuring costs Restructuring Costs Provision for income tax Unrecognized tax benefits Unrecognized Tax Benefits EX-101.PRE 10 ljpc-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 ljpc-10q_20210630_htm.xml IDEA: XBRL DOCUMENT 0000920465 2021-01-01 2021-06-30 0000920465 2021-07-23 0000920465 2021-06-30 0000920465 2020-12-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2021-06-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember 2020-12-31 0000920465 us-gaap:ProductMember 2021-04-01 2021-06-30 0000920465 us-gaap:ProductMember 2020-04-01 2020-06-30 0000920465 us-gaap:ProductMember 2021-01-01 2021-06-30 0000920465 us-gaap:ProductMember 2020-01-01 2020-06-30 0000920465 us-gaap:LicenseMember 2021-04-01 2021-06-30 0000920465 us-gaap:LicenseMember 2021-01-01 2021-06-30 0000920465 2021-04-01 2021-06-30 0000920465 2020-04-01 2020-06-30 0000920465 2020-01-01 2020-06-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000920465 us-gaap:CommonStockMember 2020-12-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000920465 us-gaap:RetainedEarningsMember 2020-12-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000920465 2021-01-01 2021-03-31 0000920465 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000920465 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000920465 us-gaap:CommonStockMember 2021-03-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000920465 us-gaap:RetainedEarningsMember 2021-03-31 0000920465 2021-03-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000920465 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000920465 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000920465 us-gaap:CommonStockMember 2021-06-30 0000920465 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000920465 us-gaap:RetainedEarningsMember 2021-06-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000920465 us-gaap:CommonStockMember 2019-12-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000920465 us-gaap:RetainedEarningsMember 2019-12-31 0000920465 2019-12-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000920465 2020-01-01 2020-03-31 0000920465 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000920465 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0000920465 us-gaap:CommonStockMember 2020-03-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000920465 us-gaap:RetainedEarningsMember 2020-03-31 0000920465 2020-03-31 0000920465 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000920465 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000920465 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000920465 ljpc:SeriesCOneConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000920465 us-gaap:CommonStockMember 2020-06-30 0000920465 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000920465 us-gaap:RetainedEarningsMember 2020-06-30 0000920465 2020-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember 2020-07-28 2020-07-28 0000920465 us-gaap:LicenseAgreementTermsMember 2021-01-12 0000920465 us-gaap:LicenseAgreementTermsMember 2021-01-11 2021-01-12 0000920465 country:US 2021-01-01 2021-06-30 0000920465 ljpc:CustomerAMember us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0000920465 ljpc:CustomerAMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-06-30 0000920465 ljpc:CustomerAMember us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0000920465 ljpc:CustomerBMember us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0000920465 ljpc:CustomerBMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-06-30 0000920465 ljpc:CustomerBMember us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0000920465 ljpc:CustomerCMember us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0000920465 ljpc:CustomerCMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-06-30 0000920465 ljpc:CustomerCMember us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0000920465 us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0000920465 us-gaap:SalesRevenueNetMember 2021-01-01 2021-06-30 0000920465 us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0000920465 us-gaap:CreditCardMember 2021-06-30 0000920465 us-gaap:CreditCardMember 2020-12-31 0000920465 ljpc:TetraphasePharmaceuticalsIncMember us-gaap:FairValueAdjustmentToInventoryMember 2021-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember us-gaap:FairValueAdjustmentToInventoryMember 2020-12-31 0000920465 us-gaap:FurnitureAndFixturesMember 2021-06-30 0000920465 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000920465 us-gaap:ComputerEquipmentMember 2021-06-30 0000920465 us-gaap:ComputerEquipmentMember 2020-12-31 0000920465 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-06-30 0000920465 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000920465 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-06-30 0000920465 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0000920465 us-gaap:TradeNamesMember 2021-06-30 0000920465 us-gaap:TradeNamesMember 2020-12-31 0000920465 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-06-30 0000920465 us-gaap:TradeNamesMember 2021-01-01 2021-06-30 0000920465 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0000920465 us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000920465 2020-04-22 0000920465 ljpc:HealthCareRoyaltyPartnersMember 2018-05-10 2018-05-10 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyAgreementPayoutPeriodOneMember 2018-05-10 2018-05-10 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyAgreementPayoutPeriodTwoMember 2018-05-10 2018-05-10 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyAgreementPayoutPeriodThreeMember 2018-05-10 2018-05-10 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2018-05-10 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2021-06-30 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2020-12-31 0000920465 ljpc:HealthCareRoyaltyPartnersMember us-gaap:OtherNoncurrentLiabilitiesMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2021-06-30 0000920465 ljpc:HealthCareRoyaltyPartnersMember us-gaap:OtherNoncurrentLiabilitiesMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2020-12-31 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2021-04-01 2021-06-30 0000920465 ljpc:HealthCareRoyaltyPartnersMember ljpc:RoyaltyFinancingAgreementMember us-gaap:LoansPayableMember 2021-01-01 2021-06-30 0000920465 ljpc:WalthamMassachusettsMember 2020-12-01 2020-12-31 0000920465 ljpc:SanDiegoCaliforniaMember 2020-09-01 2020-09-30 0000920465 ljpc:SanDiegoCaliforniaMember 2021-04-01 2021-06-30 0000920465 ljpc:SanDiegoCaliforniaMember 2021-01-01 2021-06-30 0000920465 ljpc:TwoThousandandThirteenPlanMember 2021-06-30 0000920465 ljpc:TwoThousandandThirteenPlanMember 2020-12-31 0000920465 us-gaap:EmployeeStockOptionMember ljpc:A2018EmployeeStockPurchasePlanMember 2021-06-30 0000920465 us-gaap:EmployeeStockOptionMember ljpc:A2018EmployeeStockPurchasePlanMember 2020-12-31 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0000920465 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0000920465 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000920465 ljpc:GeorgeWashingtonMember 2020-01-01 2020-03-31 0000920465 ljpc:GeorgeWashingtonMember 2021-01-01 2021-06-30 0000920465 ljpc:GeorgeWashingtonMember 2021-04-01 2021-06-30 0000920465 ljpc:GeorgeWashingtonMember 2020-04-01 2020-06-30 0000920465 ljpc:GeorgeWashingtonMember 2020-01-01 2020-06-30 0000920465 ljpc:HarvardUniversityMember 2021-01-01 2021-06-30 0000920465 ljpc:HarvardUniversityMember 2021-04-01 2021-06-30 0000920465 ljpc:ParatekPharmaceuticalsIncorporationMember 2019-03-01 2019-03-31 0000920465 ljpc:ParatekPharmaceuticalsIncorporationMember 2021-01-01 2021-06-30 0000920465 ljpc:ParatekPharmaceuticalsIncorporationMember 2021-04-01 2021-06-30 0000920465 ljpc:PAIONAGMember 2021-01-11 2021-01-12 0000920465 ljpc:PAIONAGMember 2021-01-12 0000920465 ljpc:PAIONAGMember us-gaap:SubsequentEventMember 2021-07-13 2021-07-13 0000920465 ljpc:EverestMedicinesLimitedMember 2021-06-30 0000920465 ljpc:EverestMedicinesLimitedMember 2021-01-01 2021-06-30 0000920465 ljpc:EverestMedicinesLimitedMember 2021-03-01 2021-03-31 0000920465 ljpc:EverestMedicinesLimitedMember ljpc:CommercialSupplyAgreementMember 2021-05-01 2021-05-31 0000920465 ljpc:EverestMedicinesLimitedMember ljpc:CommercialSupplyAgreementMember 2021-05-31 0000920465 ljpc:EverestMedicinesLimitedMember us-gaap:LicenseMember ljpc:CommercialSupplyAgreementMember 2021-04-01 2021-06-30 0000920465 ljpc:EverestMedicinesLimitedMember us-gaap:LicenseMember ljpc:CommercialSupplyAgreementMember 2021-01-01 2021-06-30 0000920465 ljpc:EverestMedicinesLimitedMember ljpc:CommercialSupplyAgreementMember 2021-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember 2021-01-01 2021-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember ljpc:Agreement1Member 2020-07-28 2020-07-28 0000920465 ljpc:TetraphasePharmaceuticalsIncMember ljpc:Agreement2Member 2020-07-28 2020-07-28 0000920465 ljpc:TetraphasePharmaceuticalsIncMember ljpc:Agreement3Member 2020-07-28 2020-07-28 0000920465 ljpc:TetraphasePharmaceuticalsIncMember 2020-07-28 0000920465 ljpc:TetraphasePharmaceuticalsIncMember 2021-04-01 2021-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0000920465 ljpc:TetraphasePharmaceuticalsIncMember us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0000920465 2020-01-01 2020-12-31 0000920465 ljpc:TetraphasePharmaceuticalsInc.Member 2020-01-01 2020-12-31 shares iso4217:USD iso4217:USD shares pure ljpc:Hospital ljpc:Customer 0000920465 false 2021 Q2 --12-31 P10Y P10Y P10Y P10Y P8Y3M18D P5Y8M12D 10-Q true 2021-06-30 false 1-36282 LA JOLLA PHARMACEUTICAL COMPANY CA 33-0361285 201 Jones Road Suite 400 Waltham MA 02451 617 715-3600 Common Stock, par value $0.0001 per share LJPC NASDAQ Yes Yes Non-accelerated Filer true false false 27488137 45888000 21221000 8596000 5834000 5481000 6013000 5201000 3388000 65166000 36456000 20123000 20123000 14097000 14873000 419000 536000 163000 215000 40000 40000 100008000 72243000 1846000 2762000 12175000 6494000 1912000 2878000 168000 204000 16101000 12338000 124470000 124437000 22136000 19111000 251000 332000 4493000 4112000 167451000 160330000 0.0001 0.0001 100000000 100000000 27482231 27482231 27402648 27402648 3000 3000 0.0001 0.0001 11000 11000 3906 3906 3906 3906 3906000 3906000 3906000 3906000 987249000 984756000 -1058601000 -1076752000 -67443000 -88087000 100008000 72243000 11059000 5805000 19696000 13396000 5000000 30500000 16059000 5805000 50196000 13396000 2156000 808000 4887000 1524000 3600000 8996000 8677000 17751000 16829000 1114000 8781000 2672000 17964000 12266000 18266000 28910000 36317000 3793000 -12461000 21286000 -22921000 2672000 2470000 5281000 4876000 32000 2000 222000 2532000 2532000 4085000 80000 -693000 -370000 -693000 -60000 -3131000 -3117000 -1262000 3733000 -15592000 18169000 -24183000 18000 3733000 -15592000 18151000 -24183000 0.14 -0.57 0.66 -0.89 0.11 -0.57 0.53 -0.89 27461000 27326000 27444000 27282000 34201000 27326000 34192000 27282000 4 3906000 27403 3000 984756000 -1076752000 -88087000 1116000 1116000 29 154000 154000 17 81000 81000 14418000 14418000 4 3906000 27449 3000 986107000 -1062334000 -72318000 1024000 1024000 1000 1000 33 117000 117000 3733000 3733000 4 3906000 27482 3000 987249000 -1058601000 -67443000 4 3906000 27195 3000 977432000 -1037331000 -55990000 2407000 2407000 44 305000 305000 38 200000 200000 -8591000 -8591000 4 3906000 27277 3000 980344000 -1045922000 -61669000 1590000 1590000 50 300000 300000 32 159000 159000 -15592000 -15592000 4 3906000 27359 3000 982393000 -1061514000 -75212000 18151000 -24183000 2140000 3997000 56000 1798000 3718000 3392000 850000 776000 -370000 117000 699000 -904000 -63000 2762000 -1117000 318000 909000 1813000 -1675000 -920000 -1696000 5032000 -3378000 -966000 -2591000 117000 1357000 24314000 -20595000 2860000 2999000 -139000 155000 605000 198000 359000 353000 964000 24667000 -19770000 21261000 88729000 45928000 68959000 45888000 68353000 40000 606000 45928000 68959000 1. Business La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. The Company’s consolidated financial results exclude Tetraphase’s financial results prior to the acquisition closing date of July 28, 2020 (see Note 11). In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA. As of June 30, 2021 and December 31, 2020, the Company had cash and cash equivalents of $45.9 million and $21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations. 43000000 16000000 22500000 0.15 109500000 45900000 21200000 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K. Summary of Significant Accounting Policies During the six months ended June 30, 2021, other than the license revenue recognition policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Net Product Sales</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accounts <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Receivable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer A</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer B</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="top"> Customer C</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> </table></div> Business Combinations The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred. Intangible Assets Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized. The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset. The Company recognized no impairment charge for the six months ended June 30, 2021. Goodwill Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill. The Company recognized no impairment charge for the six months ended June 30, 2021. Revenue Recognition Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. Product Sales Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.</td></tr></table></div> The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. License Revenue We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition. At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery. Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations. Basis of Presentation and Use of EstimatesThe Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Net Product Sales</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accounts <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Receivable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer A</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer B</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="top"> Customer C</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> </table></div> 399 644 The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Net Product Sales</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accounts <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Receivable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer A</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.62%;" valign="top"> Customer B</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:solid 0.75pt transparent;" valign="top"> Customer C</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> %</td> </tr> </table></div> 3 0.34 0.36 0.37 0.35 0.34 0.48 0.27 0.26 0.12 0.96 0.96 0.97 Business Combinations The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred. Intangible Assets Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized. The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset. The Company recognized no impairment charge for the six months ended June 30, 2021. 0 Goodwill Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill. The Company recognized no impairment charge for the six months ended June 30, 2021. 0 Revenue Recognition Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. Product Sales Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.</td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </td> <td style="width:1.91%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/>•</td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.</td></tr></table></div> The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. License Revenue We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition. At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery. Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations. 3. Earnings (Loss) per Share Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings (loss) per share when their effect is anti-dilutive. For the three months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 5,000 stock options. For the six months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 13,000 stock options. For the three and six months ended June 30, 2021 and 2020, there were 4.1 million and 10.2 million, respectively, of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. 6700000 6700000 5000 6700000 6700000 13000 4100000 4100000 10200000 10200000 4. Balance Sheet Details Restricted Cash Restricted cash as of June 30, 2021 and December 31, 2020 consisted of a $40,000 security deposit for the Company’s corporate purchasing credit card. Inventory, Net Inventory, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Raw materials</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">802</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">802</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Work-in-process</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,636</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,213</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Finished goods</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,043</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,998</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,481</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,013</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> As of June 30, 2021 and December 31, 2020, inventory, net included zero and $0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note 11). As of June 30, 2021 and December 31, 2020, total inventory is recorded net of inventory reserves of $1.2 million and $0.9 million, respectively. Prepaid Expenses and Other Current Assets <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Prepaid expenses and other current assets consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Refundable withholding tax</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid manufacturing costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">491</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid clinical costs</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid insurance</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"> Other prepaid expenses and current assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,133</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,201</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,388</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Furniture and fixtures</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Computer hardware</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Software</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,352</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Accumulated depreciation and amortization</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,137</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Useful Life</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="top"> Technology</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Trade name</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, gross</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,423</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(647</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,097</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,873</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The intangible assets were recorded in connection with the acquisition of Tetraphase (see Note 11). The Company recorded amortization expense of $0.4 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The Company recorded no amortization expense for the six months ended June 30, 2020. Accrued Expenses Accrued expenses consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued interest expense on deferred royalty obligation, current portion</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,227</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,567</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Deferred revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,037</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued royalties and in-license fees</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,235</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued manufacturing costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued professional fees</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"> Accrued other</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">767</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,175</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,494</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Other Noncurrent Liabilities Other noncurrent liabilities consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="top"> Paycheck Protection Program loan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,302</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="top"> Fair value of contingent value rights (see Note 11)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,180</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,810</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;" valign="top"> Total other noncurrent liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,493</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,112</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> On April 22, 2020, Tetraphase entered into a promissory note for $2.3 million under the Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for forgiveness of the PPP Loan. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default. 40000 40000 Inventory, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Raw materials</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">802</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">802</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Work-in-process</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,636</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,213</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Finished goods</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,043</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,998</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,481</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,013</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 802000 802000 3636000 3213000 1043000 1998000 5481000 6013000 0 900000 1200000 900000 Prepaid expenses and other current assets consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Refundable withholding tax</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid manufacturing costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">491</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid clinical costs</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"> Prepaid insurance</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="top"> Other prepaid expenses and current assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,133</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,201</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,388</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 3375000 491000 930000 265000 820000 263000 505000 807000 1133000 5201000 3388000 Property and equipment, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Furniture and fixtures</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> Computer hardware</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Software</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,352</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="top"> Accumulated depreciation and amortization</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,137</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 313000 309000 310000 310000 203000 733000 826000 1352000 663000 1137000 163000 215000 Intangible assets, net consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Useful Life</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="top"> Technology</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Trade name</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, gross</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:solid 0.75pt transparent;" valign="top"> Accumulated amortization</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,423</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(647</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, net</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,097</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,873</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 14000000 14000000 1520000 1520000 15520000 15520000 1423000 647000 14097000 14873000 400000 800000 0 Accrued expenses consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued interest expense on deferred royalty obligation, current portion</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,227</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,567</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Deferred revenue</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,037</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued royalties and in-license fees</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,235</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued manufacturing costs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"> Accrued professional fees</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">660</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"> Accrued other</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">767</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,175</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,494</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 4227000 3567000 3037000 188000 1235000 685000 1469000 627000 942000 660000 1265000 767000 12175000 6494000 Other noncurrent liabilities consisted of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="top"> Paycheck Protection Program loan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,313</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,302</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="top"> Fair value of contingent value rights (see Note 11)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,180</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,810</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;" valign="top"> Total other noncurrent liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,493</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,112</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 2313000 2302000 2180000 1810000 4493000 4112000 2300000 0.010 5. Deferred Royalty Obligation In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA. On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million, net of issuance costs of $0.7 million. For the three and six months ended June 30, 2021, the Company recognized interest expense, including amortization of the obligation discount, of $2.7 million and $5.3 million, respectively. For the three and six months ended June 30, 2020, the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and $4.9 million, respectively. The carrying value of the deferred royalty obligation as of June 30, 2021 and December 31, 2020 was $124.5 million and $124.4 million, respectively, net of unamortized obligation discount of $0.5 million and $0.6 million, respectively, and was classified as a noncurrent liability. The related accrued interest expense as of June 30, 2021 and December 31, 2020 was $26.4 million and $22.7 million, respectively, of which $22.1 million and $19.1 million was classified as noncurrent liabilities, respectively. During the three and six months ended June 30, 2021, the Company made royalty payments to HCR of $0.7 million and $1.6 million, respectively. As of June 30, 2021 and December 31, 2020, the Company recorded royalty obligations payable of $0.9 million and $0.9 million, respectively, in accrued expenses. The deferred royalty obligation is classified as Level 3 in the FASB ASC Topic 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value. Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of June 30, 2021 and December 31, 2020. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations. 125000000.0 125000000.0 0.10 0.04 0.04 225000000.0 125000000.0 125000000.0 700000 2700000 5300000 2500000 4900000 124500000 124400000 500000 600000 26400000 22700000 22100000 19100000 700000 1600000 900000 900000 125000000.0 225000000.0 6. Commitments and Contingencies Lease Commitments Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Thereafter</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Less: discount</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> Lease expense under current leases was approximately $0.1 million and $0.2 million for the three and six months ended June 30, 2021, respectively. Lease expense under former leases was approximately $0.7 million and $1.4 million for the three and six months ended June 30, 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities was $51,000 and $0.1 million for the three and six months ended June 30, 2021, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.0 and $1.9 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.3 years and 3.5%, respectively. Waltham Sublease In December 2020, the Company entered into a sublease agreement for office space in Waltham, Massachusetts (the “Waltham Sublease”). The Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2023. In addition to rent of approximately $15,000 per month, the Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The Waltham Sublease contains customary default provisions, representations, warranties and covenants. The Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the consolidated statements of operations and records a lease liability and right-of-use asset for this lease. San Diego Sublease In September 2020, the Company entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $28,000 and $67,000 under the San Diego Sublease during the three and six months ended June 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for this lease. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2022</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> 2023</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Thereafter</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Less: discount</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">419</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 108000 181000 166000 455000 36000 419000 100000 200000 700000 1400000 51000 100000 1000000.0 1900000 P2Y3M18D 0.035 2023-11-30 15000 P7Y 12000 P30D 28000 67000 7. Shareholders’ Equity Preferred Stock As of June 30, 2021 and December 31, 2020, 3,906 shares of Series C-12 Convertible Preferred Stock (“Series C-12 Preferred”) were issued, outstanding and convertible into 6,735,378 shares of common stock. As of June 30, 2021 and December 31, 2020, the Series C-12 Preferred liquidation preference was approximately $3.9 million. The Series C-12 Preferred does not pay a dividend. The holders of the Series C-12 Preferred do not have voting rights, other than for general protective rights required by the California General Corporation Law. 3906 3906 6735378 6735378 3900000 3900000 8. Equity Incentive Plans 2013 Equity Incentive Plan A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2021 and December 31, 2020, 5,514,933 shares of common stock and 5,478,334 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan. 2018 Employee Stock Purchase Plan A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2021 and December 31, 2020, 405,564 shares of common stock and 455,768 shares of common stock, respectively, remained available for future grants under the ESPP. Equity Awards The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Equity <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">per Share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term(1) <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value(2) <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(millions)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> Outstanding at December 31, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,121,666</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.67</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562,329</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,379</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.23</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(569,549</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.21</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> Outstanding at June 30, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,085,067</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> Exercisable at June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107,878</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.71</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> (1) Represents the weighted-average remaining contractual term of stock options. (2) Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price. Share-based Compensation Expense The classification of share-based compensation expense is summarized as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> Selling, general and administrative</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">977</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,817</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> Research and development</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,590</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> As of June 30, 2021, total unrecognized share-based compensation expense related to unvested equity awards was $8.9 million, which is expected to be recognized over a weighted-average period of 3.0 years. As of June 30, 2021, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP. 9600000 5514933 5478334 750000 405564 455768 The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Equity <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">per Share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term(1) <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value(2) <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(millions)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> Outstanding at December 31, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,121,666</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.67</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562,329</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.96</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,379</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.23</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(569,549</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.21</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> Outstanding at June 30, 2021</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,085,067</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> Exercisable at June 30, 2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107,878</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.71</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> (1) Represents the weighted-average remaining contractual term of stock options. (2) Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price. 4121666 8.67 562329 4.96 29379 5.23 569549 9.21 4085067 8.10 200000 1107878 16.71 4.28 The classification of share-based compensation expense is summarized as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.48%;" valign="top"> Selling, general and administrative</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">977</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,817</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,470</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:solid 0.75pt transparent;" valign="top"> Research and development</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">964</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,527</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,590</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,997</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 977000 626000 1817000 1470000 47000 964000 323000 2527000 1024000 1590000 2140000 3997000 8900000 P3Y 0 9. Other Income—Related Party The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the three and six months ended June 30, 2021, the Company received distributions of $2.5 million in connection with this profits interest. During the three and six months ended June 30, 2020, the Company received distributions of zero and $4.1 million, respectively, in connection with this profits interest. 2500000 2500000 0 4100000 10. License Agreements In-license Agreements George Washington University In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three and six months ended June 30, 2021, the Company made payments to GW of $0.4 million and $3.2 million, respectively. During the three and six months ended June 30, 2020, the Company made payments to GW of $0.5 million and $0.9 million, respectively. Harvard University In August 2006, the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments for the following: (i) up to approximately $15.1 million upon the achievement of certain clinical development and regulatory milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to a maximum royalty of 7.5% based on the achievement of annual net product sales thresholds; and (iv) 20% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. During the three and six months ended June 30, 2021, the Company made payments to Harvard of $1.5 million and $1.6 million, respectively, none of which related to clinical development and regulatory milestones. Paratek Pharmaceuticals, Inc. In March 2019, the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During the three and six months ended June 30, 2021, the Company paid $40,000 and $0.1 million, respectively, of royalties to Paratek. Out-license Agreements PAION AG On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones. On July 13, 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost. Everest Medicines Limited In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China National Medical Products Administration (“NMPA”) for XERAVA for the treatment of cIAI in patients in China. Amounts due under the Harvard License for this milestone payment were included as research and development expense on the consolidated statements of operations. In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license revenue during the three and six months ended June 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to June 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the performance obligation to deliver XERAVA has not yet been satisfied. 500000 0.06 0.15 400000 3200000 500000 900000 15100000 0.05 0.045 0.075 0.20 1500000 1600000 0 0 0.0225 2023-10 40000 100000 22500000 0.15 109500000 P3Y 8000000.0 20000000.0 Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. P10Y 3000000.0 6800000 4000000.0 2800000 1000000.0 1.10 5000000.0 5000000.0 2800000 11. Acquisition of Tetraphase Pharmaceuticals, Inc. On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla. The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. The estimated fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value. The Purchase Price is comprised of the upfront cash of $43 million and the estimated fair value of potential future cash payments pursuant to the CVRs. The estimated fair value of assets acquired was $54.7 million, and the estimated fair value of liabilities assumed was $9.1 million. The Purchase Price allocation as of the acquisition date is presented as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">July 28,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,990</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Fair Value of CVRs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,610</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> Total Purchase Price</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,600</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Cash and cash equivalents</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,778</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accounts receivable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Inventory</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,767</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,218</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Property and equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Right-of-use lease assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,302</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Restricted cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Identifiable intangible assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Goodwill</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,123</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accounts payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,400</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accrued expenses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,979</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Lease liabilities, current portion</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(967</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Lease liabilities, less current portion</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,420</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Other noncurrent liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,286</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> Total Purchase Price</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,600</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> The estimated fair value of potential future cash payments pursuant to the CVRs was based on a Monte Carlo simulation and is classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy. CVRs are measured at fair value on a recurring basis. During the three and six months ended June 30, 2021, the Company recorded a $0.1 million gain and $0.4 million loss, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs. The Company recorded a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost, adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from the viewpoint of a market participant. This fair value step-up adjustment is recorded as cost of product sales when the inventory is sold to customers, zero and $0.9 million of which was included in cost of product sales during the three and six months ended June 30, 2021, respectively. Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years. Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company did not make a Section 338 election. 2020-06-24 43000000 16000000 The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. 16000000 2500000 20000000 4500000 35000000 9000000 55000000 43000000 54700000 9100000 The Purchase Price allocation as of the acquisition date is presented as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">July 28,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,990</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Fair Value of CVRs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,610</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> Total Purchase Price</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,600</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Cash and cash equivalents</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,778</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accounts receivable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Inventory</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,767</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,218</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Property and equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Right-of-use lease assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,302</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Restricted cash</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Identifiable intangible assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Goodwill</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,123</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accounts payable</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,400</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Accrued expenses</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,979</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Lease liabilities, current portion</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(967</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.34%;" valign="top"> Lease liabilities, less current portion</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,420</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:solid 0.75pt transparent;" valign="top"> Other noncurrent liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,286</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> )</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.34%; border-bottom:double 2.5pt transparent;" valign="top"> Total Purchase Price</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> $</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,600</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> </td> </tr> </table></div> 42990000 2610000 45600000 8778000 1187000 4767000 1218000 58000 2302000 699000 15520000 20123000 1400000 2979000 967000 1420000 2286000 45600000 100000 -400000 3300000 0 900000 P10Y 12. Company-wide Realignments On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of June 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment. In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of June 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount. 4100000 400000 3100000 13. Income Taxes For the three and six months ended June 30, 2021, the Company recorded a provision for income taxes of zero and $18,000, respectively. For the three and six months ended June 30, 2020, the Company did not record a provision for income taxes. As of June 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were no unrecognized tax benefits as of June 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months. 0 18000 0 0 0 0 Represents the weighted-average remaining contractual term of stock options. Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2021

Jul. 23, 2021

Cover [Abstract]

Document Type 10-Q

Document Quarterly Report true

Document Transition Report false

Entity File Number 1-36282

Entity Registrant Name LA JOLLA PHARMACEUTICAL COMPANY

Entity Incorporation, State or Country Code CA

Entity Tax Identification Number 33-0361285

Entity Address, Address Line One 201 Jones Road

Entity Address, Address Line Two Suite 400

Entity Address, City or Town Waltham

Entity Address, State or Province MA

Entity Address, Postal Zip Code 02451

City Area Code 617

Local Phone Number 715-3600

Title of 12(b) Security Common Stock, par value $0.0001 per share

Trading Symbol LJPC

Security Exchange Name NASDAQ

Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Shell Company false

Entity Common Stock, Shares Outstanding 27,488,137

Entity Central Index Key 0000920465

Document Period End Date Jun. 30, 2021

Amendment Flag false

Document Fiscal Year Focus 2021

Document Fiscal Period Focus Q2

Current Fiscal Year End Date --12-31

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 308
-Subsection a
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Current assets:

Cash and cash equivalents $ 45,888 $ 21,221

Accounts receivable, net 8,596 5,834

Inventory, net 5,481 6,013

Prepaid expenses and other current assets 5,201 3,388

Total current assets 65,166 36,456

Goodwill 20,123 20,123

Intangible assets, net 14,097 14,873

Right-of-use lease assets 419 536

Property and equipment, net 163 215

Restricted cash 40 40

Total assets 100,008 72,243

Current liabilities:

Accounts payable 1,846 2,762

Accrued expenses 12,175 6,494

Accrued payroll and related expenses 1,912 2,878

Lease liabilities, current portion 168 204

Total current liabilities 16,101 12,338

Deferred royalty obligation, net 124,470 124,437

Accrued interest expense on deferred royalty obligation, less current portion 22,136 19,111

Lease liabilities, less current portion 251 332

Other noncurrent liabilities 4,493 4,112

Total liabilities 167,451 160,330

Commitments and contingencies (Note 6)

Shareholders’ deficit:

Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 3 3

Additional paid-in capital 987,249 984,756

Accumulated deficit (1,058,601) (1,076,752)

Total shareholders’ deficit (67,443) (88,087)

Total liabilities and shareholders’ deficit 100,008 72,243

Series C-1 Convertible Preferred Stock

Shareholders’ deficit:

Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020 $ 3,906 $ 3,906

X

- Definition
Accrued interest expense on deferred royalty obligation, less current portion.
+ References
No definition available.
+ Details

Name: ljpc_AccruedInterestExpenseOnDeferredRoyaltyObligationLessCurrentPortion

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Deferred Royalty Obligations
+ References
No definition available.
+ Details

Name: ljpc_DeferredRoyaltyObligations

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ljpc_SeriesCOneConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Common stock, par value (USD per share) $ 0.0001 $ 0.0001

Common stock, shares authorized (in shares) 100,000,000 100,000,000

Common stock, shares issued (in shares) 27,482,231 27,402,648

Common stock, shares outstanding (in shares) 27,482,231 27,402,648

Series C-1 Convertible Preferred Stock

Preferred stock, par value (USD per share) $ 0.0001 $ 0.0001

Preferred stock, shares authorized (in shares) 11,000 11,000

Preferred stock, shares issued (in shares) 3,906 3,906

Preferred stock, shares outstanding (in shares) 3,906 3,906

Preferred stock, liquidation $ 3,906 $ 3,906

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ljpc_SeriesCOneConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Revenue

Total revenue $ 16,059,000 $ 5,805,000 $ 50,196,000 $ 13,396,000

Operating expenses

Selling, general and administrative 8,996,000 8,677,000 17,751,000 16,829,000

Research and development 1,114,000 8,781,000 2,672,000 17,964,000

Total operating expenses 12,266,000 18,266,000 28,910,000 36,317,000

Income (loss) from operations 3,793,000 (12,461,000) 21,286,000 (22,921,000)

Other (expense) income

Interest expense (2,672,000) (2,470,000) (5,281,000) (4,876,000)

Interest income 32,000 2,000 222,000

Other income—related party 2,532,000 0 2,532,000 4,085,000

Other income (expense) 80,000 (693,000) (370,000) (693,000)

Total other (expense) income, net (60,000) (3,131,000) (3,117,000) (1,262,000)

Income (loss) before income taxes 3,733,000 (15,592,000) 18,169,000 (24,183,000)

Provision for income taxes 0 0 18,000 0

Net income (loss) $ 3,733,000 $ (15,592,000) $ 18,151,000 $ (24,183,000)

Earnings (loss) per share

Basic $ 0.14 $ (0.57) $ 0.66 $ (0.89)

Diluted $ 0.11 $ (0.57) $ 0.53 $ (0.89)

Shares used in computing earnings (loss) per share

Basic 27,461 27,326 27,444 27,282

Diluted 34,201 27,326 34,192 27,282

Product Sales

Revenue

Revenue $ 11,059,000 $ 5,805,000 $ 19,696,000 $ 13,396,000

Operating expenses

Cost of product sales, license revenue 2,156,000 $ 808,000 4,887,000 $ 1,524,000

License Revenue

Revenue

Revenue $ 5,000,000 30,500,000

Operating expenses

Cost of product sales, license revenue $ 3,600,000

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InterestIncomeExpenseNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of interest income earned from interest bearing assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)
$ in Thousands

Total

Preferred Stock

Series C-1 Convertible Preferred Stock

Common Stock

Additional Paid-in Capital

Accumulated Deficit

Beginning Balance at Dec. 31, 2019 $ (55,990) $ 3,906 $ 3 $ 977,432 $ (1,037,331)

Beginning Balance (in shares) at Dec. 31, 2019 4 27,195

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 2,407 2,407

Issuance of common stock under 2013 Equity Plan 305 305

Issuance of common stock under 2013 Equity Plan (in shares) 44

Issuance of common stock under ESPP 200 200

Issuance of common stock under ESPP (in shares) 38

Net income (loss) (8,591) (8,591)

Ending Balance at Mar. 31, 2020 (61,669) $ 3,906 $ 3 980,344 (1,045,922)

Ending Balance (in shares) at Mar. 31, 2020 4 27,277

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 2,407 2,407

Issuance of common stock under 2013 Equity Plan 305 305

Issuance of common stock under ESPP 200 200

Issuance of common stock under ESPP (in shares) 38

Net income (loss) (8,591) (8,591)

Ending Balance at Mar. 31, 2020 (61,669) $ 3,906 $ 3 980,344 (1,045,922)

Ending Balance (in shares) at Mar. 31, 2020 4 27,277

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock under 2013 Equity Plan (in shares) 44

Beginning Balance at Dec. 31, 2019 (55,990) $ 3,906 $ 3 977,432 (1,037,331)

Beginning Balance (in shares) at Dec. 31, 2019 4 27,195

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) (24,183)

Ending Balance at Jun. 30, 2020 (75,212) $ 3,906 $ 3 982,393 (1,061,514)

Ending Balance (in shares) at Jun. 30, 2020 4 27,359

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) (24,183)

Ending Balance at Jun. 30, 2020 (75,212) $ 3,906 $ 3 982,393 (1,061,514)

Ending Balance (in shares) at Jun. 30, 2020 4 27,359

Beginning Balance at Mar. 31, 2020 (61,669) $ 3,906 $ 3 980,344 (1,045,922)

Beginning Balance (in shares) at Mar. 31, 2020 4 27,277

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,590 1,590

Issuance of common stock under 2013 Equity Plan 300 300

Issuance of common stock under 2013 Equity Plan (in shares) 50

Issuance of common stock under ESPP 159 159

Issuance of common stock under ESPP (in shares) 32

Net income (loss) (15,592) (15,592)

Ending Balance at Jun. 30, 2020 (75,212) $ 3,906 $ 3 982,393 (1,061,514)

Ending Balance (in shares) at Jun. 30, 2020 4 27,359

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,590 1,590

Issuance of common stock under 2013 Equity Plan 300 300

Issuance of common stock under ESPP 159 159

Issuance of common stock under ESPP (in shares) 32

Net income (loss) (15,592) (15,592)

Ending Balance at Jun. 30, 2020 (75,212) $ 3,906 $ 3 982,393 (1,061,514)

Ending Balance (in shares) at Jun. 30, 2020 4 27,359

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock under 2013 Equity Plan (in shares) 50

Beginning Balance at Dec. 31, 2020 (88,087) $ 3,906 $ 3 984,756 (1,076,752)

Beginning Balance (in shares) at Dec. 31, 2020 4 27,403

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,116 1,116

Issuance of common stock under 2013 Equity Plan 154 154

Issuance of common stock under 2013 Equity Plan (in shares) 29

Issuance of common stock under ESPP 81 81

Issuance of common stock under ESPP (in shares) 17

Net income (loss) 14,418 14,418

Ending Balance at Mar. 31, 2021 (72,318) $ 3,906 $ 3 986,107 (1,062,334)

Ending Balance (in shares) at Mar. 31, 2021 4 27,449

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,116 1,116

Issuance of common stock under 2013 Equity Plan 154 154

Issuance of common stock under ESPP 81 81

Issuance of common stock under ESPP (in shares) 17

Net income (loss) 14,418 14,418

Ending Balance at Mar. 31, 2021 (72,318) $ 3,906 $ 3 986,107 (1,062,334)

Ending Balance (in shares) at Mar. 31, 2021 4 27,449

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock under 2013 Equity Plan (in shares) 29

Beginning Balance at Dec. 31, 2020 $ (88,087) $ 3,906 $ 3 984,756 (1,076,752)

Beginning Balance (in shares) at Dec. 31, 2020 4 27,403

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock under 2013 Equity Plan (in shares) 29,379

Net income (loss) $ 18,151

Ending Balance at Jun. 30, 2021 (67,443) $ 3,906 $ 3 987,249 (1,058,601)

Ending Balance (in shares) at Jun. 30, 2021 4 27,482

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net income (loss) 18,151

Ending Balance at Jun. 30, 2021 $ (67,443) $ 3,906 $ 3 987,249 (1,058,601)

Ending Balance (in shares) at Jun. 30, 2021 4 27,482

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock under 2013 Equity Plan (in shares) 29,379

Beginning Balance at Mar. 31, 2021 $ (72,318) $ 3,906 $ 3 986,107 (1,062,334)

Beginning Balance (in shares) at Mar. 31, 2021 4 27,449

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,024 1,024

Issuance of common stock under 2013 Equity Plan 1 1

Issuance of common stock under ESPP 117 117

Issuance of common stock under ESPP (in shares) 33

Net income (loss) 3,733 3,733

Ending Balance at Jun. 30, 2021 (67,443) $ 3,906 $ 3 987,249 (1,058,601)

Ending Balance (in shares) at Jun. 30, 2021 4 27,482

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 1,024 1,024

Issuance of common stock under 2013 Equity Plan 1 1

Issuance of common stock under ESPP 117 117

Issuance of common stock under ESPP (in shares) 33

Net income (loss) 3,733 3,733

Ending Balance at Jun. 30, 2021 $ (67,443) $ 3,906 $ 3 $ 987,249 $ (1,058,601)

Ending Balance (in shares) at Jun. 30, 2021 4 27,482

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2

Condensed Consolidated Statements of Cash Flows (Unaudited)
3 Months Ended 6 Months Ended

Jun. 30, 2021

USD ($)

Jun. 30, 2021

USD ($)

Jun. 30, 2020

USD ($)

Operating activities

Net income (loss) $ 3,733,000 $ 18,151,000 $ (24,183,000)

Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:

Share-based compensation expense 2,140,000 3,997,000

Depreciation expense 56,000 1,798,000

Non-cash interest expense 3,718,000 3,392,000

Inventory fair value step-up adjustment included in cost of product sales 850,000

Amortization of intangible assets 400,000 776,000 0

Loss on change in fair value of contingent value rights 370,000

Amortization of right-of-use lease assets 117,000 699,000

Loss on disposal of property and equipment 904,000

Unrealized gains on short-term investments (63,000)

Changes in operating assets and liabilities:

Accounts receivable, net (2,762,000) 1,117,000

Inventory, net (318,000) (909,000)

Prepaid expenses and other current assets (1,813,000) 1,675,000

Accounts payable (920,000) (1,696,000)

Accrued expenses 5,032,000 (3,378,000)

Accrued payroll and related expenses (966,000) (2,591,000)

Lease liabilities (117,000) (1,357,000)

Net cash provided by (used for) operating activities 24,314,000 (20,595,000)

Investing activities

Proceeds from the sale of property and equipment 2,860,000

Purchases of short-term investments (2,999,000)

Net cash used for investing activities (139,000)

Financing activities

Net proceeds from issuance of common stock under 2013 Equity Plan 155,000 605,000

Net proceeds from issuance of common stock under ESPP 198,000 359,000

Net cash provided by financing activities 353,000 964,000

Net increase (decrease) in cash, cash equivalents and restricted cash 24,667,000 (19,770,000)

Cash, cash equivalents and restricted cash, beginning of period 21,261,000 88,729,000

Cash, cash equivalents and restricted cash, end of period 45,928,000 45,928,000 68,959,000

Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets

Cash and cash equivalents 45,888,000 45,888,000 68,353,000

Restricted cash 40,000 40,000 606,000

Cash, cash equivalents and restricted cash, end of period $ 45,928,000 $ 45,928,000 $ 68,959,000

X

- Definition
Amortization of right-of-use lease assets.
+ References
No definition available.
+ Details

Name: ljpc_AmortizationOfRightOfUseLeaseAssets

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase (Decrease) Operating Lease, Liability
+ References
No definition available.
+ Details

Name: ljpc_IncreaseDecreaseOperatingLeaseLiability

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Loss on change in fair value of contingent value rights.
+ References
No definition available.
+ Details

Name: ljpc_LossOnChangeInFairValueOfContingentValueRights

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Non-Cash Interest Expense
+ References
No definition available.
+ Details

Name: ljpc_NonCashInterestExpense

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds From Issuance Of Common Stock From Employee Share Purchase Program
+ References
No definition available.
+ Details

Name: ljpc_ProceedsFromIssuanceOfCommonStockFromEmployeeSharePurchaseProgram

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrealized Gains On Short-Term Investments
+ References
No definition available.
+ Details

Name: ljpc_UnrealizedGainsOnShortTermInvestments

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in accrued expenses, and obligations classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2

Business
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Business
1. Business

La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA^™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA^™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. The Company’s consolidated financial results exclude Tetraphase’s financial results prior to the acquisition closing date of July 28, 2020 (see Note 11).

In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA.

As of June 30, 2021 and December 31, 2020, the Company had cash and cash equivalents of $45.9 million and $21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies
2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K.

Summary of Significant Accounting Policies

During the six months ended June 30, 2021, other than the license revenue recognition policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.

During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales:

U.S. Net Product Sales

Accounts

Receivable

Three Months Ended

June 30, 2021

Six Months Ended

June 30, 2021

As of June 30, 2021

Customer A

34

%

36

%

37

%

Customer B

35

%

34

%

48

%

Customer C

27

%

26

%

12

%

Total

96

%

96

%

97

%

Business Combinations

The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized.

The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Goodwill

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized.

The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Revenue Recognition

Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations.

Product Sales

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

•

Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.

•

Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.

The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.

License Revenue

We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones.

If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.

At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs.

For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings (Loss) per Share
6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Earnings (Loss) per Share
3. Earnings (Loss) per Share

Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings (loss) per share when their effect is anti-dilutive. For the three months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 5,000 stock options. For the six months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 13,000 stock options. For the three and six months ended June 30, 2021 and 2020, there were 4.1 million and 10.2 million, respectively, of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Account Details
4. Balance Sheet Details

Restricted Cash

Restricted cash as of June 30, 2021 and December 31, 2020 consisted of a $40,000 security deposit for the Company’s corporate purchasing credit card.

Inventory, Net

Inventory, net consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Raw materials

$

802

$

802

Work-in-process

3,636

3,213

Finished goods

1,043

1,998

Total inventory, net

$

5,481

$

6,013

As of June 30, 2021 and December 31, 2020, inventory, net included zero and $0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note 11). As of June 30, 2021 and December 31, 2020, total inventory is recorded net of inventory reserves of $1.2 million and $0.9 million, respectively.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Refundable withholding tax

$

3,375

$

-

Prepaid manufacturing costs

491

930

Prepaid clinical costs

265

820

Prepaid insurance

263

505

Other prepaid expenses and current assets

807

1,133

Total prepaid expenses and other current assets

$

5,201

$

3,388

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Furniture and fixtures

$

313

$

309

Computer hardware

310

310

Software

203

733

Total property and equipment, gross

826

1,352

Accumulated depreciation and amortization

(663

)

(1,137

)

Total property and equipment, net

$

163

$

215

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

Useful Life

June 30,

December 31,

(years)

2021

2020

Technology

10

$

14,000

$

14,000

Trade name

10

1,520

1,520

Total intangible assets, gross

15,520

15,520

Accumulated amortization

(1,423

)

(647

)

Total intangible assets, net

$

14,097

$

14,873

The intangible assets were recorded in connection with the acquisition of Tetraphase (see Note 11). The Company recorded amortization expense of $0.4 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The Company recorded no amortization expense for the six months ended June 30, 2020.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Accrued interest expense on deferred royalty obligation, current portion

$

4,227

$

3,567

Deferred revenue

3,037

188

Accrued royalties and in-license fees

1,235

685

Accrued manufacturing costs

1,469

627

Accrued professional fees

942

660

Accrued other

1,265

767

Total accrued expenses

$

12,175

$

6,494

Other Noncurrent Liabilities

Other noncurrent liabilities consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Paycheck Protection Program loan

$

2,313

$

2,302

Fair value of contingent value rights (see Note 11)

2,180

1,810

Total other noncurrent liabilities

$

4,493

$

4,112

On April 22, 2020, Tetraphase entered into a promissory note for $2.3 million under the Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for forgiveness of the PPP Loan. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2

Deferred Royalty Obligation
6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Deferred Royalty Obligation

5. Deferred Royalty Obligation

In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.

On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million, net of issuance costs of $0.7 million. For the three and six months ended June 30, 2021, the Company recognized interest expense, including amortization of the obligation discount, of $2.7 million and $5.3 million, respectively. For the three and six months ended June 30, 2020, the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and $4.9 million, respectively. The carrying value of the deferred royalty obligation as of June 30, 2021 and December 31, 2020 was $124.5 million and $124.4 million, respectively, net of unamortized obligation discount of $0.5 million and $0.6 million, respectively, and was classified as a noncurrent liability. The related accrued interest expense as of June 30, 2021 and December 31, 2020 was $26.4 million and $22.7 million, respectively, of which $22.1 million and $19.1 million was classified as noncurrent liabilities, respectively. During the three and six months ended June 30, 2021, the Company made royalty payments to HCR of $0.7 million and $1.6 million, respectively. As of June 30, 2021 and December 31, 2020, the Company recorded royalty obligations payable of $0.9 million and $0.9 million, respectively, in accrued expenses. The deferred royalty obligation is classified as Level 3 in the FASB ASC Topic 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value.

Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of June 30, 2021 and December 31, 2020. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments and Contingencies
6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Commitments and Contingencies
6. Commitments and Contingencies

Lease Commitments

Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands):

2021

$

108

2022

181

2023

166

Thereafter

-

Total future minimum lease payments

455

Less: discount

36

Total lease liabilities

$

419

Lease expense under current leases was approximately $0.1 million and $0.2 million for the three and six months ended June 30, 2021, respectively. Lease expense under former leases was approximately $0.7 million and $1.4 million for the three and six months ended June 30, 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities was $51,000 and $0.1 million for the three and six months ended June 30, 2021, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.0 and $1.9 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.3 years and 3.5%, respectively.

Waltham Sublease

In December 2020, the Company entered into a sublease agreement for office space in Waltham, Massachusetts (the “Waltham Sublease”). The Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2023. In addition to rent of approximately $15,000 per month, the Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The Waltham Sublease contains customary default provisions, representations, warranties and covenants. The Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the consolidated statements of operations and records a lease liability and right-of-use asset for this lease.

San Diego Sublease

In September 2020, the Company entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $28,000 and $67,000 under the San Diego Sublease during the three and six months ended June 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for this lease.

Contingencies

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders Equity
6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Shareholders Equity

7. Shareholders’ Equity

Preferred Stock

As of June 30, 2021 and December 31, 2020, 3,906 shares of Series C-1² Convertible Preferred Stock (“Series C-1²Preferred”) were issued, outstanding and convertible into 6,735,378 shares of common stock. As of June 30, 2021 and December 31, 2020, the Series C-1² Preferred liquidation preference was approximately $3.9 million. The Series C-1² Preferred does not pay a dividend. The holders of the Series C-1² Preferred do not have voting rights, other than for general protective rights required by the California General Corporation Law.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans
6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Incentive Plans
8. Equity Incentive Plans

2013 Equity Incentive Plan

A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2021 and December 31, 2020, 5,514,933 shares of common stock and 5,478,334 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan.

2018 Employee Stock Purchase Plan

A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2021 and December 31, 2020, 405,564 shares of common stock and 455,768 shares of common stock, respectively, remained available for future grants under the ESPP.

Equity Awards

The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows:

Equity

Awards

Weighted-

average

Exercise Price

per Share

Weighted-

average

Remaining

Contractual

Term⁽¹⁾

(years)

Aggregate

Intrinsic

Value⁽²⁾

(millions)

Outstanding at December 31, 2020

4,121,666

$

8.67

Granted

562,329

$

4.96

Exercised

(29,379

)

$

5.23

Cancelled/forfeited

(569,549

)

$

9.21

Outstanding at June 30, 2021

4,085,067

$

8.10

8.3

$

0.2

Exercisable at June 30, 2021

1,107,878

$

16.71

5.7

$

-

⁽¹⁾Represents the weighted-average remaining contractual term of stock options.

⁽²⁾ Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

Share-based Compensation Expense

The classification of share-based compensation expense is summarized as follows (in thousands):

Three Months Ended

Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Selling, general and administrative

$

977

$

626

$

1,817

$

1,470

Research and development

47

964

323

2,527

Total share-based compensation expense

$

1,024

$

1,590

$

2,140

$

3,997

As of June 30, 2021, total unrecognized share-based compensation expense related to unvested equity awards was $8.9 million, which is expected to be recognized over a weighted-average period of 3.0 years. As of June 30, 2021, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

X

- Definition
The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-URI http://asc.fasb.org/topic&trid=2197446

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-URI http://asc.fasb.org/topic&trid=2127225

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2

Other Income—Related Party
6 Months Ended

Jun. 30, 2021

Related Party Transactions [Abstract]

Other Income—Related Party
9. Other Income—Related Party

The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the three and six months ended June 30, 2021, the Company received distributions of $2.5 million in connection with this profits interest. During the three and six months ended June 30, 2020, the Company received distributions of zero and $4.1 million, respectively, in connection with this profits interest.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2

License Agreements
6 Months Ended

Jun. 30, 2021

Research And Development [Abstract]

License Agreements
10. License Agreements

In-license Agreements

George Washington University

In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three and six months ended June 30, 2021, the Company made payments to GW of $0.4 million and $3.2 million, respectively. During the three and six months ended June 30, 2020, the Company made payments to GW of $0.5 million and $0.9 million, respectively.

Harvard University

In August 2006, the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments for the following: (i) up to approximately $15.1 million upon the achievement of certain clinical development and regulatory milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to a maximum royalty of 7.5% based on the achievement of annual net product sales thresholds; and (iv) 20% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. During the three and six months ended June 30, 2021, the Company made payments to Harvard of $1.5 million and $1.6 million, respectively, none of which related to clinical development and regulatory milestones.

Paratek Pharmaceuticals, Inc.

In March 2019, the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During the three and six months ended June 30, 2021, the Company paid $40,000 and $0.1 million, respectively, of royalties to Paratek.

Out-license Agreements

PAION AG

On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

On July 13, 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost.

Everest Medicines Limited

In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China National Medical Products Administration (“NMPA”) for XERAVA for the treatment of cIAI in patients in China. Amounts due under the Harvard License for this milestone payment were included as research and development expense on the consolidated statements of operations.

In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license revenue during the three and six months ended June 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to June 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the performance obligation to deliver XERAVA has not yet been satisfied.

X

- Definition
Licensed Technology Agreement [Text Block]
+ References
No definition available.
+ Details

Name: ljpc_LicensedTechnologyAgreementTextBlock

Namespace Prefix: ljpc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2

Acquisition of Tetraphase Pharmaceuticals, Inc
6 Months Ended

Jun. 30, 2021

Business Combinations [Abstract]

Acquisition of Tetraphase Pharmaceuticals, Inc

11. Acquisition of Tetraphase Pharmaceuticals, Inc.

On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla.

The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. The estimated fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value.

The Purchase Price is comprised of the upfront cash of $43 million and the estimated fair value of potential future cash payments pursuant to the CVRs. The estimated fair value of assets acquired was $54.7 million, and the estimated fair value of liabilities assumed was $9.1 million.

The Purchase Price allocation as of the acquisition date is presented as follows (in thousands):

July 28,

2020

Cash

$

42,990

Fair Value of CVRs

2,610

Total Purchase Price

$

45,600

Cash and cash equivalents

$

8,778

Accounts receivable

1,187

Inventory

4,767

Prepaid expenses and other current assets

1,218

Property and equipment

58

Right-of-use lease assets

2,302

Restricted cash

699

Identifiable intangible assets

15,520

Goodwill

20,123

Accounts payable

(1,400

)

Accrued expenses

(2,979

)

Lease liabilities, current portion

(967

)

Lease liabilities, less current portion

(1,420

)

Other noncurrent liabilities

(2,286

)

Total Purchase Price

$

45,600

The estimated fair value of potential future cash payments pursuant to the CVRs was based on a Monte Carlo simulation and is classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy.

CVRs are measured at fair value on a recurring basis. During the three and six months ended June 30, 2021, the Company recorded a $0.1 million gain and $0.4 million loss, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs.

The Company recorded a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost, adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from the viewpoint of a market participant. This fair value step-up adjustment is recorded as cost of product sales when the inventory is sold to customers, zero and $0.9 million of which was included in cost of product sales during the three and six months ended June 30, 2021, respectively.

Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years.

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company did not make a Section 338 election.

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2

Company-wide Realignment
6 Months Ended

Jun. 30, 2021

Restructuring And Related Activities [Abstract]

Company-wide Realignments
12. Company-wide Realignments

On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of June 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment.

In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of June 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount.

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes
6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes
13. Income Taxes

For the three and six months ended June 30, 2021, the Company recorded a provision for income taxes of zero and $18,000, respectively. For the three and six months ended June 30, 2020, the Company did not record a provision for income taxes. As of June 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were no unrecognized tax benefits as of June 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation
Basis of Presentation and Use of Estimates
The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”).

Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

Use of Estimates
The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K.

Concentration of Credit Risk
Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.

During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales:

U.S. Net Product Sales

Accounts

Receivable

Three Months Ended

June 30, 2021

Six Months Ended

June 30, 2021

As of June 30, 2021

Customer A

34

%

36

%

37

%

Customer B

35

%

34

%

48

%

Customer C

27

%

26

%

12

%

Total

96

%

96

%

97

%

Business Combinations
Business Combinations

The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets
Intangible Assets

Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized.

The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Goodwill
Goodwill

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized.

The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

The Company recognized no impairment charge for the six months ended June 30, 2021.

Revenue Recognition
Revenue Recognition

Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations.

Product Sales

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

•

Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.

•

Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.

The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.

License Revenue

We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones.

If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.

At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs.

For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.

Recent Accounting Pronouncements
Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations.

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 05
-Paragraph 4
-Subparagraph (a)-(d)
-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Concentration Risk The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales:

U.S. Net Product Sales

Accounts

Receivable

Three Months Ended

June 30, 2021

Six Months Ended

June 30, 2021

As of June 30, 2021

Customer A

34

%

36

%

37

%

Customer B

35

%

34

%

48

%

Customer C

27

%

26

%

12

%

Total

96

%

96

%

97

%

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details (Tables)
6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Inventory
Inventory, net consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Raw materials

$

802

$

802

Work-in-process

3,636

3,213

Finished goods

1,043

1,998

Total inventory, net

$

5,481

$

6,013

Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Refundable withholding tax

$

3,375

$

-

Prepaid manufacturing costs

491

930

Prepaid clinical costs

265

820

Prepaid insurance

263

505

Other prepaid expenses and current assets

807

1,133

Total prepaid expenses and other current assets

$

5,201

$

3,388

Property, Plant and Equipment
Property and equipment, net consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Furniture and fixtures

$

313

$

309

Computer hardware

310

310

Software

203

733

Total property and equipment, gross

826

1,352

Accumulated depreciation and amortization

(663

)

(1,137

)

Total property and equipment, net

$

163

$

215

Schedule of Intangible Assets, Net
Intangible assets, net consisted of the following (in thousands):

Useful Life

June 30,

December 31,

(years)

2021

2020

Technology

10

$

14,000

$

14,000

Trade name

10

1,520

1,520

Total intangible assets, gross

15,520

15,520

Accumulated amortization

(1,423

)

(647

)

Total intangible assets, net

$

14,097

$

14,873

Accrued Expenses
Accrued expenses consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Accrued interest expense on deferred royalty obligation, current portion

$

4,227

$

3,567

Deferred revenue

3,037

188

Accrued royalties and in-license fees

1,235

685

Accrued manufacturing costs

1,469

627

Accrued professional fees

942

660

Accrued other

1,265

767

Total accrued expenses

$

12,175

$

6,494

Schedule of Other Noncurrent Liabilities
Other noncurrent liabilities consisted of the following (in thousands):

June 30,

December 31,

2021

2020

Paycheck Protection Program loan

$

2,313

$

2,302

Fair value of contingent value rights (see Note 11)

2,180

1,810

Total other noncurrent liabilities

$

4,493

$

4,112

X

- Definition
Schedule of prepaid expenses and other current asset.
+ References
No definition available.
+ Details

Name: ljpc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock

Namespace Prefix: ljpc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other noncurrent liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_OtherNoncurrentLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments and Contingencies (Tables)
6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Schedule of Future Minimum Lease Payments Excluding Operating Costs
Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands):

2021

$

108

2022

181

2023

166

Thereafter

-

Total future minimum lease payments

455

Less: discount

36

Total lease liabilities

$

419

X

- Definition
Schedule of future minimum lease payments excluding operating costs.
+ References
No definition available.
+ Details

Name: ljpc_ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock

Namespace Prefix: ljpc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans (Tables)
6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Award Activity
The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows:

Equity

Awards

Weighted-

average

Exercise Price

per Share

Weighted-

average

Remaining

Contractual

Term⁽¹⁾

(years)

Aggregate

Intrinsic

Value⁽²⁾

(millions)

Outstanding at December 31, 2020

4,121,666

$

8.67

Granted

562,329

$

4.96

Exercised

(29,379

)

$

5.23

Cancelled/forfeited

(569,549

)

$

9.21

Outstanding at June 30, 2021

4,085,067

$

8.10

8.3

$

0.2

Exercisable at June 30, 2021

1,107,878

$

16.71

5.7

$

-

⁽¹⁾Represents the weighted-average remaining contractual term of stock options.

⁽²⁾ Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

Share-based Compensation Expense
The classification of share-based compensation expense is summarized as follows (in thousands):

Three Months Ended

Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Selling, general and administrative

$

977

$

626

$

1,817

$

1,470

Research and development

47

964

323

2,527

Total share-based compensation expense

$

1,024

$

1,590

$

2,140

$

3,997

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2

Acquisition of Tetraphase Pharmaceuticals, Inc (Tables)
6 Months Ended

Jun. 30, 2021

Business Combinations [Abstract]

Summary of Purchase Price Allocation as of Acquisition Date
The Purchase Price allocation as of the acquisition date is presented as follows (in thousands):

July 28,

2020

Cash

$

42,990

Fair Value of CVRs

2,610

Total Purchase Price

$

45,600

Cash and cash equivalents

$

8,778

Accounts receivable

1,187

Inventory

4,767

Prepaid expenses and other current assets

1,218

Property and equipment

58

Right-of-use lease assets

2,302

Restricted cash

699

Identifiable intangible assets

15,520

Goodwill

20,123

Accounts payable

(1,400

)

Accrued expenses

(2,979

)

Lease liabilities, current portion

(967

)

Lease liabilities, less current portion

(1,420

)

Other noncurrent liabilities

(2,286

)

Total Purchase Price

$

45,600

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2

Business - Additional Information (Details) - USD ($)
$ in Thousands

Jan. 12, 2021

Jul. 28, 2020

Jun. 30, 2021

Dec. 31, 2020

Jun. 30, 2020

Business Acquisition [Line Items]

Cash and cash equivalents $ 45,888 $ 21,221 $ 68,353

License Agreement

Business Acquisition [Line Items]

Proceeds from upfront cash payment $ 22,500

Percentage of refundable tax withholding 15.00%

Commercial milestone payments $ 109,500

Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Upfront cash for acquisition $ 42,990

Future cash payments $ 16,000

X

- Definition
Commercial Milestone Payments.
+ References
No definition available.
+ Details

Name: ljpc_CommercialMilestonePayments

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage of refundable tax withholding.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfRefundableTaxWithholding

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds from upfront cash payment.
+ References
No definition available.
+ Details

Name: ljpc_ProceedsFromUpfrontCashPayment

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The quantified amount of the future effect on cash flows.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_EffectOnFutureCashFlowsAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
6 Months Ended

Jun. 30, 2021

USD ($)

Hospital

Customer

Concentration Risk [Line Items]

Number of major customers | Customer 3

Impairment of intangible assets | $ $ 0

Goodwill impairment charges | $ $ 0

U.S.

Concentration Risk [Line Items]

Number of hospitals purchased GIAPREZA | Hospital 399

Number of hospitals and other healthcare organizations purchased XERAVA | Hospital 644

X

- Definition
Number of hospitals and other healthcare organizations purchased XERAVA.
+ References
No definition available.
+ Details

Name: ljpc_NumberOfHospitalsAndOtherHealthcareOrganizationsPurchasedXERAVA

Namespace Prefix: ljpc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of hospitals purchased GIAPREZA.
+ References
No definition available.
+ Details

Name: ljpc_NumberOfHospitalsPurchasedGIAPREZA

Namespace Prefix: ljpc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of major customers.
+ References
No definition available.
+ Details

Name: ljpc_NumberOfMajorCustomers

Namespace Prefix: ljpc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetImpairment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2021

U.S. Net Product Sales

Concentration Risk [Line Items]

Concentration of credit risk 96.00% 96.00%

Accounts Receivable

Concentration Risk [Line Items]

Concentration of credit risk 97.00%

Customer A | U.S. Net Product Sales

Concentration Risk [Line Items]

Concentration of credit risk 34.00% 36.00%

Customer A | Accounts Receivable

Concentration Risk [Line Items]

Concentration of credit risk 37.00%

Customer B | U.S. Net Product Sales

Concentration Risk [Line Items]

Concentration of credit risk 35.00% 34.00%

Customer B | Accounts Receivable

Concentration Risk [Line Items]

Concentration of credit risk 48.00%

Customer C | U.S. Net Product Sales

Concentration Risk [Line Items]

Concentration of credit risk 27.00% 26.00%

Customer C | Accounts Receivable

Concentration Risk [Line Items]

Concentration of credit risk 12.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=ljpc_CustomerAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=ljpc_CustomerBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=ljpc_CustomerCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings (Loss) per Share - Additional Information (Details) - shares
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Earnings Per Share [Abstract]

Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares) 4,100,000 4,100,000 10,200,000 10,200,000

Potential common shares that were included in the calculation of diluted earnings per share 6,700,000 6,700,000

Issuance of common stock up on conversion of preferred stock 6,700,000 6,700,000

Stock options 5,000 13,000

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 40
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Apr. 22, 2020

Restricted Cash And Cash Equivalents Items [Line Items]

Restricted cash $ 40,000 $ 40,000 $ 606,000

Inventory, net 5,481,000 5,481,000 $ 6,013,000

Inventory reserves 1,200,000 1,200,000 900,000

Amortization expense 400,000 776,000 $ 0

Promissory note $ 2,300,000

Debt instrument, interest rate 1.00%

Tetraphase Pharmaceuticals, Inc. | Fair Value Step-Up Adjustment to Inventory

Restricted Cash And Cash Equivalents Items [Line Items]

Inventory, net 0 0 900,000

Credit Card

Restricted Cash And Cash Equivalents Items [Line Items]

Restricted cash $ 40,000 $ 40,000 $ 40,000

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_CreditCardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Schedule of Inventory (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Raw materials $ 802 $ 802

Work-in-process 3,636 3,213

Finished goods 1,043 1,998

Total inventory, net $ 5,481 $ 6,013

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Prepaid Expense And Other Assets [Abstract]

Refundable withholding tax $ 3,375

Prepaid manufacturing costs 491 $ 930

Prepaid clinical costs 265 820

Prepaid insurance 263 505

Other prepaid expenses and current assets 807 1,133

Total prepaid expenses and other current assets $ 5,201 $ 3,388

X

- Definition
Other prepaid expenses and current assets.
+ References
No definition available.
+ Details

Name: ljpc_OtherPrepaidExpensesAndCurrentAssets

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Prepaid clinical costs current.
+ References
No definition available.
+ Details

Name: ljpc_PrepaidClinicalCostsCurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Prepaid manufacturing costs, current.
+ References
No definition available.
+ Details

Name: ljpc_PrepaidManufacturingCostsCurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Refundable withholding tax current.
+ References
No definition available.
+ Details

Name: ljpc_RefundableWithholdingTaxCurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Property Plant and Equipment (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Property Plant And Equipment [Line Items]

Total property and equipment, gross $ 826 $ 1,352

Accumulated depreciation and amortization (663) (1,137)

Total property and equipment, net 163 215

Furniture and Fixtures [Member]

Property Plant And Equipment [Line Items]

Total property and equipment, gross 313 309

Computer Equipment [Member]

Property Plant And Equipment [Line Items]

Total property and equipment, gross 310 310

Software and Software Development Costs [Member]

Property Plant And Equipment [Line Items]

Total property and equipment, gross $ 203 $ 733

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Schedule of Intangible Assets, Net (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2021

Dec. 31, 2020

Finite Lived Intangible Assets [Line Items]

Total intangible assets, gross $ 15,520 $ 15,520

Accumulated amortization (1,423) (647)

Total intangible assets, net 14,097 14,873

Technology

Finite Lived Intangible Assets [Line Items]

Total intangible assets, gross $ 14,000 $ 14,000

Useful Life (years) 10 years 10 years

Trade Name

Finite Lived Intangible Assets [Line Items]

Total intangible assets, gross $ 1,520 $ 1,520

Useful Life (years) 10 years 10 years

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Accrued interest expense on deferred royalty obligation, current portion $ 4,227 $ 3,567

Deferred revenue 3,037 188

Accrued royalties and in-license fees 1,235 685

Accrued manufacturing costs 1,469 627

Accrued professional fees 942 660

Accrued other 1,265 767

Total accrued expenses $ 12,175 $ 6,494

X

- Definition
Accrued interest expense on deferred royalty obligation, current.
+ References
No definition available.
+ Details

Name: ljpc_AccruedInterestExpenseOnDeferredRoyaltyObligationCurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Manufacturing Costs
+ References
No definition available.
+ Details

Name: ljpc_AccruedManufacturingCosts

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued royalties and in-license fees current.
+ References
No definition available.
+ Details

Name: ljpc_AccruedRoyaltiesAndInLicenseFeesCurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2

Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Other Liabilities Noncurrent [Abstract]

Paycheck Protection Program loan $ 2,313 $ 2,302

Fair value of contingent value rights (see Note 11) 2,180 1,810

Total other noncurrent liabilities $ 4,493 $ 4,112

X

- Definition
Fair value of contingent value rights noncurrent.
+ References
No definition available.
+ Details

Name: ljpc_FairValueOfContingentValueRightsNoncurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Paycheck protection program loan noncurrent.
+ References
No definition available.
+ Details

Name: ljpc_PaycheckProtectionProgramLoanNoncurrent

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2

Deferred Royalty Obligation - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

May 10, 2018

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Debt Instrument [Line Items]

Deferred royalty obligation, net $ 124,470 $ 124,470 $ 124,437

Interest expense 2,700 $ 2,500 5,300 $ 4,900

Royalty obligation payable 900 900 900

HealthCare Royalty Partners

Debt Instrument [Line Items]

Proceeds from royalty agreement $ 125,000

Required payment for breach of agreement, payment two 225,000

Required payment for breach of agreement, payment one 125,000

HealthCare Royalty Partners | Royalty Financing Agreement | Loans Payable

Debt Instrument [Line Items]

Deferred royalty obligation, net 125,000 124,500 124,500 124,400

Debt issuance costs $ 700

Unamortized debt discount 500 500 600

Accrued interest expense 26,400 26,400 22,700

Royalty payments 700 1,600

HealthCare Royalty Partners | Royalty Financing Agreement | Loans Payable | Other Noncurrent Liabilities

Debt Instrument [Line Items]

Accrued interest expense $ 22,100 $ 22,100 $ 19,100

HealthCare Royalty Partners | Period One

Debt Instrument [Line Items]

Maximum potential royalty payout 10.00%

HealthCare Royalty Partners | Period Two

Debt Instrument [Line Items]

Increase in maximum potential payout percent 4.00%

HealthCare Royalty Partners | Payout Period

Debt Instrument [Line Items]

Increase in maximum potential payout percent 4.00%

X

- Definition
Deferred Royalty Obligations
+ References
No definition available.
+ Details

Name: ljpc_DeferredRoyaltyObligations

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Royalty Agreement, Amount Funded
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyAgreementAmountFunded

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Royalty Agreement, Increase In Maximum Potential Payout, Percent
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty Agreement, Maximum Potential Payout, Percent
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyAgreementMaximumPotentialPayoutPercent

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty Agreement, Required Payment For Breach Of Agreement, Payment One
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Royalty Agreement, Required Payment For Breach Of Agreement, Payment Two
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Royalty Obligation Payable
+ References
No definition available.
+ Details

Name: ljpc_RoyaltyObligationPayable

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate amount of interest expense on all borrowings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.7,8)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpenseBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_HealthCareRoyaltyPartnersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ljpc_RoyaltyFinancingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ljpc_RoyaltyAgreementPayoutPeriodAxis=ljpc_RoyaltyAgreementPayoutPeriodOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ljpc_RoyaltyAgreementPayoutPeriodAxis=ljpc_RoyaltyAgreementPayoutPeriodTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: ljpc_RoyaltyAgreementPayoutPeriodAxis=ljpc_RoyaltyAgreementPayoutPeriodThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)
$ in Thousands

Jun. 30, 2021

USD ($)

Leases [Abstract]

2021 $ 108

2022 181

2023 166

Total future minimum lease payments 455

Less: discount 36

Total lease liabilities $ 419

X

- Definition
Lessee operating lease liability payments excluding lease operating cost due.
+ References
No definition available.
+ Details

Name: ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee operating lease liability payments excluding lease operating cost, undiscounted excess amount.
+ References
No definition available.
+ Details

Name: ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostUndiscountedExcessAmount

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee operating lease liability payments excluding lease operating costs due next twelve months.
+ References
No definition available.
+ Details

Name: ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueNextTwelveMonths

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee operating lease liability payments excluding lease operating costs due remainder of fiscal year.
+ References
No definition available.
+ Details

Name: ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueRemainderOfFiscalYear

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee operating lease liability payments excluding lease operating costs due year two.
+ References
No definition available.
+ Details

Name: ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueYearTwo

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Lessee Lease Description [Line Items]

Lease expense $ 100,000 $ 700,000 $ 200,000 $ 1,400,000

Operating lease, cash payments $ 51,000 $ 1,000,000.0 $ 100,000 $ 1,900,000

Operating lease weighted-average remaining lease term 2 years 3 months 18 days 2 years 3 months 18 days

Operating lease weighted-average discount rate 3.50% 3.50%

Waltham Sublease

Lessee Lease Description [Line Items]

Expiration date Nov. 30, 2023

Sublease rent per month $ 15,000

San Diego Sublease

Lessee Lease Description [Line Items]

Sublease rent per month $ 12,000

Sublease term 7 years

Sublease cancellable written notice period 30 days

Payments of sublease $ 28,000 $ 67,000

X

- Definition
Payments of sublease.
+ References
No definition available.
+ Details

Name: ljpc_PaymentsOfSublease

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sublease cancellable written notice period.
+ References
No definition available.
+ Details

Name: ljpc_SubleaseCancellableWrittenNoticePeriod

Namespace Prefix: ljpc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Sublease rent expense per month.
+ References
No definition available.
+ Details

Name: ljpc_SubleaseRentExpensePerMonth

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sublease term.
+ References
No definition available.
+ Details

Name: ljpc_SubleaseTerm

Namespace Prefix: ljpc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=ljpc_WalthamMassachusettsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=ljpc_SanDiegoCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders' Equity - Additional Information (Details) - Series C-1 Convertible Preferred Stock - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Class Of Stock [Line Items]

Preferred stock, shares issued (in shares) 3,906 3,906

Convertible Preferred Stock, Shares Reserved for Future Issuance 6,735,378 6,735,378

Preferred stock, liquidation preference $ 3,906 $ 3,906

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=ljpc_SeriesCOneConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans - Narrative (Details) - USD ($)
6 Months Ended

Jun. 30, 2021

Dec. 31, 2020

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unamortized share-based compensation expense $ 8,900,000

Recognized weighted average period 3 years

2013 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares reserved for issuance 9,600,000

Shares available for grant (in shares) 5,514,933 5,478,334

2018 Employee Stock Purchase Plan [Member] | Share-based Payment Arrangement, Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares reserved for issuance 750,000

Shares available for grant (in shares) 405,564 455,768

Unrecognized share-based compensation expense $ 0

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=ljpc_TwoThousandandThirteenPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ljpc_A2018EmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans - Stock Option Activity (Details)
$ / shares in Units, $ in Millions
6 Months Ended

Jun. 30, 2021

USD ($)

$ / shares

shares

Shares Underlying Stock Options

Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares) | shares 4,121,666

Granted, Shares underlying stock options and restricted stock awards (in shares) | shares 562,329

Exercised, Shares underlying stock options and restricted stock awards (in shares) | shares (29,379)

Cancelled/Forfeited, Shares underlying stock options and restricted stock awards (in shares) | shares (569,549)

Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares) | shares 4,085,067

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Shares | shares 1,107,878

Weighted- Average Exercise Price per Share

Outstanding beginning balance, Weighted - average exercise price (usd per share) | $ / shares $ 8.67

Granted, Weighted - average exercise price (usd per share) | $ / shares 4.96

Exercised, Weighted - average exercise price (usd per share) | $ / shares 5.23

Cancelled/forfeited, Weighted - average exercise price (usd per share) | $ / shares 9.21

Outstanding ending balance, Weighted - average exercise price (usd per share) | $ / shares 8.10

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares $ 16.71

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 8 years 3 months 18 days ^[1]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 5 years 8 months 12 days ^[1]

Outstanding, Aggregate Intrinsic Value | $ $ 0.2 ^[2]

[1] Represents the weighted-average remaining contractual term of stock options.

[2] Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)
6 Months Ended

Jun. 30, 2021

$ / shares

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Change of equity awards outstanding or equity awards, exercise price $ 4.28

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Change in the weighted average exercise price of options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2

Equity Incentive Plans - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense $ 1,024 $ 1,590 $ 2,140 $ 3,997

Selling, General and Administrative Expenses [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense 977 626 1,817 1,470

Research and development [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based compensation expense $ 47 $ 964 $ 323 $ 2,527

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2

Other Income-Related Party - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Related Party Transactions [Abstract]

Other income—related party $ 2,532,000 $ 0 $ 2,532,000 $ 4,085,000

X

- Definition
Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2

License Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Jul. 13, 2021

Jan. 12, 2021

May 31, 2021

Mar. 31, 2021

Mar. 31, 2019

Jun. 30, 2021

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2021

Jun. 30, 2020

License Revenue

Research And Development Arrangement Contract To Perform For Others [Line Items]

Revenue $ 5,000,000 $ 30,500,000

George Washington

Research And Development Arrangement Contract To Perform For Others [Line Items]

Milestone payment $ 500,000

Percentage of royalty on net sales 6.00%

Percentage of payments received from sublicensee 15.00%

Royalty payments 400,000 $ 500,000 $ 3,200,000 $ 900,000

Harvard

Research And Development Arrangement Contract To Perform For Others [Line Items]

Percentage of royalty on net sales 5.00%

Percentage of payments received from sublicensee 20.00%

Clinical development and regulatory milestones amount payable $ 15,100,000

Percentage of minimum royalty rate 4.50%

Percentage of maximum royalty based on achievement of annual net product sales thresholds 7.50%

Royalties payments 1,500,000 $ 1,600,000

Payments related to clinical development and regulatory milestones 0 0

Paratek

Research And Development Arrangement Contract To Perform For Others [Line Items]

Percentage of royalty on net sales 2.25%

Royalties payments 40,000 $ 100,000

Claim expiration 2023-10

PAION AG

Research And Development Arrangement Contract To Perform For Others [Line Items]

Milestone payment $ 109,500,000

Upfront cash payment $ 22,500,000

Percentage of refundable tax withholding 15.00%

PAION AG | Subsequent Event

Research And Development Arrangement Contract To Perform For Others [Line Items]

Supply agreement term 3 years

Everest Medicines Limited

Research And Development Arrangement Contract To Perform For Others [Line Items]

Additional regulatory milestone payments receivable 8,000,000.0 $ 8,000,000.0

Sales milestone payments receivable 20,000,000.0 $ 20,000,000.0

Royalties payable description Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.

Royalties payable period after first commercial sale of product 10 years

Milestone payments received $ 3,000,000.0

Everest Medicines Limited | Commercial Supply Agreement

Research And Development Arrangement Contract To Perform For Others [Line Items]

Proceeds from upfront payments $ 6,800,000

Proceeds from upfront technology transfer payment 4,000,000.0

Proceeds from partial prepayment for XERAVA 2,800,000

Additional technology transfer payment receivable by January 30, 2022 $ 1,000,000.0

Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023 110.00%

Deferred revenue 2,800,000 $ 2,800,000

Everest Medicines Limited | Commercial Supply Agreement | License Revenue

Research And Development Arrangement Contract To Perform For Others [Line Items]

Revenue $ 5,000,000.0 $ 5,000,000.0

X

- Definition
Additional technology transfer payment receivable.
+ References
No definition available.
+ Details

Name: ljpc_AdditionalTechnologyTransferPaymentReceivable

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Claim expiration date.
+ References
No definition available.
+ Details

Name: ljpc_ClaimExpirationDate

Namespace Prefix: ljpc_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Clinical development and regulatory milestones amount payable.
+ References
No definition available.
+ Details

Name: ljpc_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments for clinical development and regulatory milestone.
+ References
No definition available.
+ Details

Name: ljpc_PaymentsForClinicalDevelopmentAndRegulatoryMilestone

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of maximum royalty based on achievement of annual net product sales thresholds.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of minimum royalty rate.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfMinimumRoyaltyRate

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of refundable tax withholding.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfRefundableTaxWithholding

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of reimbursed for direct and certain indirect manufacturing costs.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of royalty on net sales.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfRoyaltyOnNetSales

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of royalty payments on behalf of sublicensee.
+ References
No definition available.
+ Details

Name: ljpc_PercentageOfRoyaltyPaymentsOnBehalfOfSublicensee

Namespace Prefix: ljpc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Proceeds from partial prepayment for XERAVA.
+ References
No definition available.
+ Details

Name: ljpc_ProceedsFromPartialPrepaymentForXERAVA

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from upfront payments.
+ References
No definition available.
+ Details

Name: ljpc_ProceedsFromUpfrontPayments

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from upfront technology transfer payment.
+ References
No definition available.
+ Details

Name: ljpc_ProceedsFromUpfrontTechnologyTransferPayment

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Regulatory milestone payments receivable.
+ References
No definition available.
+ Details

Name: ljpc_RegulatoryMilestonePaymentsReceivable

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Royalties payable description.
+ References
No definition available.
+ Details

Name: ljpc_RoyaltiesPayableDescription

Namespace Prefix: ljpc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalties payable period after first commercial sale of product.
+ References
No definition available.
+ Details

Name: ljpc_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct

Namespace Prefix: ljpc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Sales milestone payments receivable.
+ References
No definition available.
+ Details

Name: ljpc_SalesMilestonePaymentsReceivable

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Supply agreement term.
+ References
No definition available.
+ Details

Name: ljpc_SupplyAgreementTerm

Namespace Prefix: ljpc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Upfront Cash Payment.
+ References
No definition available.
+ Details

Name: ljpc_UpfrontCashPayment

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of cash paid for royalties during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRoyalties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received from collaborators during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromCollaborators

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_GeorgeWashingtonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_HarvardUniversityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_ParatekPharmaceuticalsIncorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_PAIONAGMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=ljpc_EverestMedicinesLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ljpc_CommercialSupplyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2

Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jul. 28, 2020

Jun. 30, 2021

Jun. 30, 2021

Business Acquisition [Line Items]

Inventory fair value step up adjustment $ 850,000

Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Business acquisition, date of acquisition agreement Jun. 24, 2020

Upfront cash for acquisition $ 42,990,000

Future cash payments 16,000,000

Additional aggregate payments 16,000,000

Business acquisition, description The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.

Estimated fair value of assets acquired 54,700,000

Estimated fair value of liabilities assumed 9,100,000

Gail (loss) recorded in other (expense) income resulting from the change in fair value of CVRs $ 100,000 $ (400,000)

Inventory fair value step up adjustment $ 3,300,000

Weighted-average Years 10 years

Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales

Business Acquisition [Line Items]

Inventory fair value step up adjustment $ 0 $ 900,000

Agreement 1 | Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Proceeds from businesses and interest in affiliates $ 2,500,000

Net sales from related parties 20,000,000

Agreement 2 | Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Proceeds from businesses and interest in affiliates 4,500,000

Net sales from related parties 35,000,000

Agreement 3 | Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Proceeds from businesses and interest in affiliates 9,000,000

Net sales from related parties $ 55,000,000

X

- Definition
Fair value measurement with reconciliation recurring basis gain (loss) included in other income (expense).
+ References
No definition available.
+ Details

Name: ljpc_FairValueMeasurementWithReconciliationRecurringBasisGainLossIncludedInOtherIncomeExpense

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the business acquisition agreement was executed, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460
+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The quantified amount of the future effect on cash flows.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_EffectOnFutureCashFlowsAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=ljpc_Agreement1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=ljpc_Agreement2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TransactionTypeAxis=ljpc_Agreement3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2

Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) - USD ($)
$ in Thousands

Jul. 28, 2020

Jun. 30, 2021

Dec. 31, 2020

Business Acquisition [Line Items]

Goodwill $ 20,123 $ 20,123

Tetraphase Pharmaceuticals, Inc.

Business Acquisition [Line Items]

Cash $ 42,990

Fair Value of CVRs 2,610

Total Purchase Price 45,600

Cash and cash equivalents 8,778

Accounts receivable 1,187

Inventory 4,767

Prepaid expenses and other current assets 1,218

Property and equipment 58

Right-of-use lease assets 2,302

Restricted cash 699

Identifiable intangible assets 15,520

Goodwill 20,123

Accounts payable (1,400)

Accrued expenses (2,979)

Lease liabilities, current portion (967)

Lease liabilities, less current portion (1,420)

Other noncurrent liabilities $ (2,286)

X

- Definition
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.
+ References
No definition available.
+ Details

Name: ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Business combination recognized identifiable assets acquired and liabilities assumed lease liabilities, less current portion.
+ References
No definition available.
+ Details

Name: ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilitiesLessCurrentPortion

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.
+ References
No definition available.
+ Details

Name: ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business combination recognized identifiable assets acquired and liabilities assumed right-of-use lease assets.
+ References
No definition available.
+ Details

Name: ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of contingent value rights.
+ References
No definition available.
+ Details

Name: ljpc_FairValueOfContingentValueRights

Namespace Prefix: ljpc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of lease obligation assumed in business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2

Company-wide Realignments - Additional Information (Details)
$ in Millions
12 Months Ended

Dec. 31, 2020

USD ($)

Restructuring Cost And Reserve [Line Items]

Reversal of non-cash-stock-based compensation expense $ 0.4

Restructuring costs 4.1

Tetraphase Pharmaceuticals, Inc.

Restructuring Cost And Reserve [Line Items]

Restructuring costs $ 3.1

X

- Definition
Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ljpc_TetraphasePharmaceuticalsInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Provision for income tax $ 0 $ 0 $ 18,000 $ 0

Unrecognized tax benefits $ 0 $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 150 352 1 true 48 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Business Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusiness Business Notes 7 false false R8.htm 100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Earnings (Loss) per Share Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShare Earnings (Loss) per Share Notes 9 false false R10.htm 100090 - Disclosure - Balance Sheet Details Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 10 false false R11.htm 100100 - Disclosure - Deferred Royalty Obligation Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligation Deferred Royalty Obligation Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingencies Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 100120 - Disclosure - Shareholders Equity Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquity Shareholders Equity Notes 13 false false R14.htm 100130 - Disclosure - Equity Incentive Plans Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlans Equity Incentive Plans Notes 14 false false R15.htm 100140 - Disclosure - Other Income???Related Party Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedParty Other Income???Related Party Notes 15 false false R16.htm 100150 - Disclosure - License Agreements Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreements License Agreements Notes 16 false false R17.htm 100160 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsInc Acquisition of Tetraphase Pharmaceuticals, Inc Notes 17 false false R18.htm 100170 - Disclosure - Company-wide Realignment Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignment Company-wide Realignment Notes 18 false false R19.htm 100180 - Disclosure - Income Taxes Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetails 22 false false R23.htm 100220 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies 23 false false R24.htm 100230 - Disclosure - Equity Incentive Plans (Tables) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlans 24 false false R25.htm 100240 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc (Tables) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncTables Acquisition of Tetraphase Pharmaceuticals, Inc (Tables) Tables http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsInc 25 false false R26.htm 100250 - Disclosure - Business - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails Business - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Details 27 false false R28.htm 100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) Details 28 false false R29.htm 100280 - Disclosure - Earnings (Loss) per Share - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails Earnings (Loss) per Share - Additional Information (Details) Details http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShare 29 false false R30.htm 100290 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails Balance Sheet Details - Schedule of Inventory (Details) Details 31 false false R32.htm 100310 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Details - Property Plant and Equipment (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails Balance Sheet Details - Property Plant and Equipment (Details) Details 33 false false R34.htm 100330 - Disclosure - Balance Sheet Details - Schedule of Intangible Assets, Net (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails Balance Sheet Details - Schedule of Intangible Assets, Net (Details) Details 34 false false R35.htm 100340 - Disclosure - Balance Sheet Details - Summary of Accrued Expenses (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails Balance Sheet Details - Summary of Accrued Expenses (Details) Details 35 false false R36.htm 100350 - Disclosure - Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) Details 36 false false R37.htm 100360 - Disclosure - Deferred Royalty Obligation - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails Deferred Royalty Obligation - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details) Details 38 false false R39.htm 100390 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 39 false false R40.htm 100400 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 40 false false R41.htm 100410 - Disclosure - Equity Incentive Plans - Narrative (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails Equity Incentive Plans - Narrative (Details) Details 41 false false R42.htm 100420 - Disclosure - Equity Incentive Plans - Stock Option Activity (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails Equity Incentive Plans - Stock Option Activity (Details) Details 42 false false R43.htm 100430 - Disclosure - Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityParentheticalDetails Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details) Details 43 false false R44.htm 100440 - Disclosure - Equity Incentive Plans - Share-based Compensation Expense (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails Equity Incentive Plans - Share-based Compensation Expense (Details) Details 44 false false R45.htm 100450 - Disclosure - Other Income-Related Party - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedPartyAdditionalInformationDetails Other Income-Related Party - Additional Information (Details) Details 45 false false R46.htm 100460 - Disclosure - License Agreements - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails License Agreements - Additional Information (Details) Details 46 false false R47.htm 100470 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) Details 47 false false R48.htm 100480 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) Details 48 false false R49.htm 100490 - Disclosure - Company-wide Realignments - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails Company-wide Realignments - Additional Information (Details) Details 49 false false R50.htm 100500 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 50 false false All Reports Book All Reports ljpc-10q_20210630.htm ljpc-20210630.xsd ljpc-20210630_cal.xml ljpc-20210630_def.xml ljpc-20210630_lab.xml ljpc-20210630_pre.xml ljpc-ex311_6.htm ljpc-ex312_7.htm ljpc-ex321_8.htm g4vfo5s522gp000001.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ljpc-10q_20210630.htm": { "axisCustom": 1, "axisStandard": 22, "contextCount": 150, "dts": { "calculationLink": { "local": [ "ljpc-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ljpc-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ljpc-10q_20210630.htm" ] }, "labelLink": { "local": [ "ljpc-20210630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ljpc-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ljpc-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 444, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 8, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 13 }, "keyCustom": 65, "keyStandard": 287, "memberCustom": 24, "memberStandard": 24, "nsprefix": "ljpc", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Balance Sheet Details", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Deferred Royalty Obligation", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligation", "shortName": "Deferred Royalty Obligation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Commitments and Contingencies", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Shareholders Equity", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquity", "shortName": "Shareholders Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Equity Incentive Plans", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlans", "shortName": "Equity Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Other Income\u2014Related Party", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedParty", "shortName": "Other Income\u2014Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ljpc:LicensedTechnologyAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - License Agreements", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ljpc:LicensedTechnologyAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsInc", "shortName": "Acquisition of Tetraphase Pharmaceuticals, Inc", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Company-wide Realignment", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignment", "shortName": "Company-wide Realignment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Balance Sheet Details (Tables)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ljpc:ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "ljpc:ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Equity Incentive Plans (Tables)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansTables", "shortName": "Equity Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc (Tables)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncTables", "shortName": "Acquisition of Tetraphase Pharmaceuticals, Inc (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Business - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails", "shortName": "Business - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20210112", "decimals": "-5", "lang": null, "name": "ljpc:ProceedsFromUpfrontCashPayment", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "ljpc:NumberOfMajorCustomers", "reportCount": 1, "unique": true, "unitRef": "U_ljpcCustomer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "ljpc:NumberOfMajorCustomers", "reportCount": 1, "unique": true, "unitRef": "U_ljpcCustomer", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_20210401_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_20210401_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Earnings (Loss) per Share - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails", "shortName": "Earnings (Loss) per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "shortName": "Balance Sheet Details - Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ljpc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:RefundableWithholdingTaxCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ljpc:ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:RefundableWithholdingTaxCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Balance Sheet Details - Property Plant and Equipment (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails", "shortName": "Balance Sheet Details - Property Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Balance Sheet Details - Schedule of Intangible Assets, Net (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails", "shortName": "Balance Sheet Details - Schedule of Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:AccruedInterestExpenseOnDeferredRoyaltyObligationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Balance Sheet Details - Summary of Accrued Expenses (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails", "shortName": "Balance Sheet Details - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:AccruedInterestExpenseOnDeferredRoyaltyObligationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:PaycheckProtectionProgramLoanNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:PaycheckProtectionProgramLoanNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:DeferredRoyaltyObligations", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Deferred Royalty Obligation - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails", "shortName": "Deferred Royalty Obligation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpenseBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ljpc:ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails", "shortName": "Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ljpc:ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "ljpc:LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapStatementClassOfStockAxis_ljpcSeriesCOneConvertiblePreferredStockMember_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Shareholders' Equity - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "shortName": "Shareholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapStatementClassOfStockAxis_ljpcSeriesCOneConvertiblePreferredStockMember_20210630", "decimals": "INF", "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Equity Incentive Plans - Narrative (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails", "shortName": "Equity Incentive Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Equity Incentive Plans - Stock Option Activity (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails", "shortName": "Equity Incentive Plans - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityParentheticalDetails", "shortName": "Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Equity Incentive Plans - Share-based Compensation Expense (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails", "shortName": "Equity Incentive Plans - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Other Income-Related Party - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedPartyAdditionalInformationDetails", "shortName": "Other Income-Related Party - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_srtProductOrServiceAxis_us-gaapLicenseMember_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - License Agreements - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "shortName": "License Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ljpc:LicensedTechnologyAgreementTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_srtCounterpartyNameAxis_ljpcGeorgeWashingtonMember_20200101_20200331", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "shortName": "Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapBusinessAcquisitionAxis_ljpcTetraphasePharmaceuticalsIncMember_20200728_20200728", "decimals": null, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "shortName": "Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_us-gaapBusinessAcquisitionAxis_ljpcTetraphasePharmaceuticalsIncMember_20200728", "decimals": "-3", "lang": null, "name": "ljpc:FairValueOfContingentValueRights", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Company-wide Realignments - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails", "shortName": "Company-wide Realignments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited", "shortName": "Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:UnrecognizedTaxBenefits", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Business", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusiness", "shortName": "Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Earnings (Loss) per Share", "role": "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShare", "shortName": "Earnings (Loss) per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ljpc-10q_20210630.htm", "contextRef": "C_0000920465_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "verboseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "verboseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ljpc_A2018EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Employee Stock Purchase Plan [Member]", "label": "A2018 Employee Stock Purchase Plan [Member]", "terseLabel": "2018 Employee Stock Purchase Plan [Member]" } } }, "localname": "A2018EmployeeStockPurchasePlanMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "ljpc_AccruedInterestExpenseOnDeferredRoyaltyObligationCurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest expense on deferred royalty obligation, current.", "label": "Accrued Interest Expense On Deferred Royalty Obligation Current", "terseLabel": "Accrued interest expense on deferred royalty obligation, current portion" } } }, "localname": "AccruedInterestExpenseOnDeferredRoyaltyObligationCurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_AccruedInterestExpenseOnDeferredRoyaltyObligationLessCurrentPortion": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest expense on deferred royalty obligation, less current portion.", "label": "Accrued Interest Expense On Deferred Royalty Obligation Less Current Portion", "terseLabel": "Accrued interest expense on deferred royalty obligation, less current portion" } } }, "localname": "AccruedInterestExpenseOnDeferredRoyaltyObligationLessCurrentPortion", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ljpc_AccruedManufacturingCosts": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Manufacturing Costs", "label": "Accrued Manufacturing Costs", "terseLabel": "Accrued manufacturing costs" } } }, "localname": "AccruedManufacturingCosts", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_AccruedRoyaltiesAndInLicenseFeesCurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued royalties and in-license fees current.", "label": "Accrued Royalties And In License Fees Current", "terseLabel": "Accrued royalties and in-license fees" } } }, "localname": "AccruedRoyaltiesAndInLicenseFeesCurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_AdditionalTechnologyTransferPaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional technology transfer payment receivable.", "label": "Additional Technology Transfer Payment Receivable", "terseLabel": "Additional technology transfer payment receivable by January 30, 2022" } } }, "localname": "AdditionalTechnologyTransferPaymentReceivable", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_Agreement1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement 1 [Member]", "label": "Agreement1 [Member]", "terseLabel": "Agreement 1" } } }, "localname": "Agreement1Member", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_Agreement2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement 2 [Member]", "label": "Agreement2 [Member]", "terseLabel": "Agreement 2" } } }, "localname": "Agreement2Member", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_Agreement3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement 3 [Member]", "label": "Agreement3 [Member]", "terseLabel": "Agreement 3" } } }, "localname": "Agreement3Member", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_AmortizationOfRightOfUseLeaseAssets": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of right-of-use lease assets.", "label": "Amortization Of Right Of Use Lease Assets", "terseLabel": "Amortization of right-of-use lease assets" } } }, "localname": "AmortizationOfRightOfUseLeaseAssets", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10110.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses", "negatedLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilitiesLessCurrentPortion": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10130.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed lease liabilities, less current portion.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Lease Liabilities Less Current Portion", "negatedLabel": "Lease liabilities, less current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilitiesLessCurrentPortion", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10070.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10060.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed right-of-use lease assets.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Lease Assets", "terseLabel": "Right-of-use lease assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLeaseAssets", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_ClaimExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Claim expiration date.", "label": "Claim Expiration Date", "terseLabel": "Claim expiration" } } }, "localname": "ClaimExpirationDate", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "ljpc_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Clinical development and regulatory milestones amount payable.", "label": "Clinical Development And Regulatory Milestones Amount Payable", "terseLabel": "Clinical development and regulatory milestones amount payable" } } }, "localname": "ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_CommercialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commercial Milestone Payments.", "label": "Commercial Milestone Payments", "terseLabel": "Commercial milestone payments" } } }, "localname": "CommercialMilestonePayments", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_CommercialSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial supply agreement.", "label": "Commercial Supply Agreement [Member]", "terseLabel": "Commercial Supply Agreement" } } }, "localname": "CommercialSupplyAgreementMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "ljpc_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "ljpc_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "ljpc_DeferredRoyaltyObligations": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Royalty Obligations", "label": "Deferred Royalty Obligations", "terseLabel": "Deferred royalty obligation, net" } } }, "localname": "DeferredRoyaltyObligations", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ljpc_EverestMedicinesLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Everest medicines limited.", "label": "Everest Medicines Limited [Member]", "terseLabel": "Everest Medicines Limited" } } }, "localname": "EverestMedicinesLimitedMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_FairValueMeasurementWithReconciliationRecurringBasisGainLossIncludedInOtherIncomeExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with reconciliation recurring basis gain (loss) included in other income (expense).", "label": "Fair Value Measurement With Reconciliation Recurring Basis Gain Loss Included In Other Income Expense", "terseLabel": "Gail (loss) recorded in other (expense) income resulting from the change in fair value of CVRs" } } }, "localname": "FairValueMeasurementWithReconciliationRecurringBasisGainLossIncludedInOtherIncomeExpense", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_FairValueOfContingentValueRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent value rights.", "label": "Fair Value Of Contingent Value Rights", "terseLabel": "Fair Value of CVRs" } } }, "localname": "FairValueOfContingentValueRights", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_FairValueOfContingentValueRightsNoncurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent value rights noncurrent.", "label": "Fair Value Of Contingent Value Rights Noncurrent", "terseLabel": "Fair value of contingent value rights (see Note 11)" } } }, "localname": "FairValueOfContingentValueRightsNoncurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_GeorgeWashingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GeorgeWashington [Member]", "label": "George Washington [Member]", "terseLabel": "George Washington" } } }, "localname": "GeorgeWashingtonMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_HarvardUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Harvard University.", "label": "Harvard University [Member]", "terseLabel": "Harvard" } } }, "localname": "HarvardUniversityMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_HealthCareRoyaltyPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HealthCare Royalty Partners [Member]", "label": "Health Care Royalty Partners [Member]", "terseLabel": "HealthCare Royalty Partners" } } }, "localname": "HealthCareRoyaltyPartnersMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_IncreaseDecreaseOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Operating Lease, Liability", "label": "Increase Decrease Operating Lease Liability", "negatedLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseOperatingLeaseLiability", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating cost due.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Cost Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails2": { "order": 10010.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating cost, undiscounted excess amount.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Cost Undiscounted Excess Amount", "terseLabel": "Less: discount" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostUndiscountedExcessAmount", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails": { "order": 10020.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating costs due next twelve months.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueNextTwelveMonths", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails": { "order": 10010.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating costs due remainder of fiscal year.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Remainder Of Fiscal Year", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueRemainderOfFiscalYear", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueThereafter": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails": { "order": 10040.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating costs due thereafter.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueThereafter", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails": { "order": 10030.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments excluding lease operating costs due year two.", "label": "Lessee Operating Lease Liability Payments Excluding Lease Operating Costs Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostsDueYearTwo", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_LicensedTechnologyAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensed Technology Agreement [Text Block]", "label": "Licensed Technology Agreement [Text Block]", "terseLabel": "License Agreements" } } }, "localname": "LicensedTechnologyAgreementTextBlock", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "ljpc_LossOnChangeInFairValueOfContingentValueRights": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss on change in fair value of contingent value rights.", "label": "Loss On Change In Fair Value Of Contingent Value Rights", "negatedLabel": "Loss on change in fair value of contingent value rights" } } }, "localname": "LossOnChangeInFairValueOfContingentValueRights", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Interest Expense", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_NumberOfHospitalsAndOtherHealthcareOrganizationsPurchasedXERAVA": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of hospitals and other healthcare organizations purchased XERAVA.", "label": "Number Of Hospitals And Other Healthcare Organizations Purchased X E R A V A", "terseLabel": "Number of hospitals and other healthcare organizations purchased XERAVA" } } }, "localname": "NumberOfHospitalsAndOtherHealthcareOrganizationsPurchasedXERAVA", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ljpc_NumberOfHospitalsPurchasedGIAPREZA": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of hospitals purchased GIAPREZA.", "label": "Number Of Hospitals Purchased G I A P R E Z A", "terseLabel": "Number of hospitals purchased GIAPREZA" } } }, "localname": "NumberOfHospitalsPurchasedGIAPREZA", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ljpc_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number Of Major Customers", "terseLabel": "Number of major customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ljpc_OtherPrepaidExpensesAndCurrentAssets": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other prepaid expenses and current assets.", "label": "Other Prepaid Expenses And Current Assets", "terseLabel": "Other prepaid expenses and current assets" } } }, "localname": "OtherPrepaidExpensesAndCurrentAssets", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_PAIONAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PAION AG.", "label": "P A I O N A G [Member]", "terseLabel": "PAION AG" } } }, "localname": "PAIONAGMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_ParatekPharmaceuticalsIncorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paratek Pharmaceuticals, Incorporation.", "label": "Paratek Pharmaceuticals Incorporation [Member]", "terseLabel": "Paratek" } } }, "localname": "ParatekPharmaceuticalsIncorporationMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_PaycheckProtectionProgramLoanNoncurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Paycheck protection program loan noncurrent.", "label": "Paycheck Protection Program Loan Noncurrent", "terseLabel": "Paycheck Protection Program loan" } } }, "localname": "PaycheckProtectionProgramLoanNoncurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_PaymentsForClinicalDevelopmentAndRegulatoryMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments for clinical development and regulatory milestone.", "label": "Payments For Clinical Development And Regulatory Milestone", "terseLabel": "Payments related to clinical development and regulatory milestones" } } }, "localname": "PaymentsForClinicalDevelopmentAndRegulatoryMilestone", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_PaymentsOfSublease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of sublease.", "label": "Payments Of Sublease", "terseLabel": "Payments of sublease" } } }, "localname": "PaymentsOfSublease", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum royalty based on achievement of annual net product sales thresholds.", "label": "Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds", "terseLabel": "Percentage of maximum royalty based on achievement of annual net product sales thresholds" } } }, "localname": "PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PercentageOfMinimumRoyaltyRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum royalty rate.", "label": "Percentage Of Minimum Royalty Rate", "terseLabel": "Percentage of minimum royalty rate" } } }, "localname": "PercentageOfMinimumRoyaltyRate", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PercentageOfRefundableTaxWithholding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of refundable tax withholding.", "label": "Percentage Of Refundable Tax Withholding", "terseLabel": "Percentage of refundable tax withholding" } } }, "localname": "PercentageOfRefundableTaxWithholding", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of reimbursed for direct and certain indirect manufacturing costs.", "label": "Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs", "terseLabel": "Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023" } } }, "localname": "PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PercentageOfRoyaltyOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on net sales.", "label": "Percentage Of Royalty On Net Sales", "terseLabel": "Percentage of royalty on net sales" } } }, "localname": "PercentageOfRoyaltyOnNetSales", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PercentageOfRoyaltyPaymentsOnBehalfOfSublicensee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty payments on behalf of sublicensee.", "label": "Percentage Of Royalty Payments On Behalf Of Sublicensee", "terseLabel": "Percentage of payments received from sublicensee" } } }, "localname": "PercentageOfRoyaltyPaymentsOnBehalfOfSublicensee", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_PrepaidClinicalCostsCurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid clinical costs current.", "label": "Prepaid Clinical Costs Current", "terseLabel": "Prepaid clinical costs" } } }, "localname": "PrepaidClinicalCostsCurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_PrepaidManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid manufacturing costs, current.", "label": "Prepaid Manufacturing Costs Current", "terseLabel": "Prepaid manufacturing costs" } } }, "localname": "PrepaidManufacturingCostsCurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_ProceedsFromIssuanceOfCommonStockFromEmployeeSharePurchaseProgram": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Common Stock From Employee Share Purchase Program", "label": "Proceeds From Issuance Of Common Stock From Employee Share Purchase Program", "terseLabel": "Net proceeds from issuance of common stock under ESPP" } } }, "localname": "ProceedsFromIssuanceOfCommonStockFromEmployeeSharePurchaseProgram", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_ProceedsFromPartialPrepaymentForXERAVA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from partial prepayment for XERAVA.", "label": "Proceeds From Partial Prepayment For X E R A V A", "terseLabel": "Proceeds from partial prepayment for XERAVA" } } }, "localname": "ProceedsFromPartialPrepaymentForXERAVA", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_ProceedsFromUpfrontCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from upfront cash payment.", "label": "Proceeds From Upfront Cash Payment", "terseLabel": "Proceeds from upfront cash payment" } } }, "localname": "ProceedsFromUpfrontCashPayment", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_ProceedsFromUpfrontPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from upfront payments.", "label": "Proceeds From Upfront Payments", "terseLabel": "Proceeds from upfront payments" } } }, "localname": "ProceedsFromUpfrontPayments", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_ProceedsFromUpfrontTechnologyTransferPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from upfront technology transfer payment.", "label": "Proceeds From Upfront Technology Transfer Payment", "terseLabel": "Proceeds from upfront technology transfer payment" } } }, "localname": "ProceedsFromUpfrontTechnologyTransferPayment", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RefundableWithholdingTaxCurrent": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refundable withholding tax current.", "label": "Refundable Withholding Tax Current", "terseLabel": "Refundable withholding tax" } } }, "localname": "RefundableWithholdingTaxCurrent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RegulatoryMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payments receivable.", "label": "Regulatory Milestone Payments Receivable", "terseLabel": "Additional regulatory milestone payments receivable" } } }, "localname": "RegulatoryMilestonePaymentsReceivable", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RoyaltiesPayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payable description.", "label": "Royalties Payable Description", "terseLabel": "Royalties payable description" } } }, "localname": "RoyaltiesPayableDescription", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ljpc_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payable period after first commercial sale of product.", "label": "Royalties Payable Period After First Commercial Sale Of Product", "terseLabel": "Royalties payable period after first commercial sale of product" } } }, "localname": "RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ljpc_RoyaltyAgreementAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Amount Funded", "label": "Royalty Agreement Amount Funded", "terseLabel": "Proceeds from royalty agreement" } } }, "localname": "RoyaltyAgreementAmountFunded", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Increase In Maximum Potential Payout, Percent", "label": "Royalty Agreement Increase In Maximum Potential Payout Percent", "terseLabel": "Increase in maximum potential payout percent" } } }, "localname": "RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_RoyaltyAgreementMaximumPotentialPayoutPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Maximum Potential Payout, Percent", "label": "Royalty Agreement Maximum Potential Payout Percent", "terseLabel": "Maximum potential royalty payout" } } }, "localname": "RoyaltyAgreementMaximumPotentialPayoutPercent", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ljpc_RoyaltyAgreementPayoutPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Payout Period [Axis]", "label": "Royalty Agreement Payout Period [Axis]", "terseLabel": "Royalty Agreement Payout Period" } } }, "localname": "RoyaltyAgreementPayoutPeriodAxis", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ljpc_RoyaltyAgreementPayoutPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Royalty Agreement, Payout Period [Axis]", "label": "Royalty Agreement Payout Period [Domain]", "terseLabel": "Royalty Agreement Payout Period" } } }, "localname": "RoyaltyAgreementPayoutPeriodDomain", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_RoyaltyAgreementPayoutPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Payout Period One [Member]", "label": "Royalty Agreement Payout Period One [Member]", "terseLabel": "Period One" } } }, "localname": "RoyaltyAgreementPayoutPeriodOneMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_RoyaltyAgreementPayoutPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Payout Period Three [Member]", "label": "Royalty Agreement Payout Period Three [Member]", "terseLabel": "Payout Period" } } }, "localname": "RoyaltyAgreementPayoutPeriodThreeMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_RoyaltyAgreementPayoutPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Payout Period Two [Member]", "label": "Royalty Agreement Payout Period Two [Member]", "terseLabel": "Period Two" } } }, "localname": "RoyaltyAgreementPayoutPeriodTwoMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Required Payment For Breach Of Agreement, Payment One", "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment One", "terseLabel": "Required payment for breach of agreement, payment one" } } }, "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Agreement, Required Payment For Breach Of Agreement, Payment Two", "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment Two", "terseLabel": "Required payment for breach of agreement, payment two" } } }, "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_RoyaltyFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Financing Agreement [Member]", "label": "Royalty Financing Agreement [Member]", "terseLabel": "Royalty Financing Agreement" } } }, "localname": "RoyaltyFinancingAgreementMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_RoyaltyObligationPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Obligation Payable", "label": "Royalty Obligation Payable", "terseLabel": "Royalty obligation payable" } } }, "localname": "RoyaltyObligationPayable", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_SalesMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales milestone payments receivable.", "label": "Sales Milestone Payments Receivable", "terseLabel": "Sales milestone payments receivable" } } }, "localname": "SalesMilestonePaymentsReceivable", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_SanDiegoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Diego California.", "label": "San Diego California [Member]", "terseLabel": "San Diego Sublease" } } }, "localname": "SanDiegoCaliforniaMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum lease payments excluding operating costs.", "label": "Schedule Of Future Minimum Lease Payments Excluding Operating Costs Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Excluding Operating Costs" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsExcludingOperatingCostsTableTextBlock", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "ljpc_ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and other current asset.", "label": "Schedule Of Prepaid Expenses And Other Current Asset Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetTableTextBlock", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "ljpc_SeriesCOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C One Convertible Preferred Stock [Member]", "label": "Series C One Convertible Preferred Stock [Member]", "terseLabel": "Series C-1 Convertible Preferred Stock" } } }, "localname": "SeriesCOneConvertiblePreferredStockMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "ljpc_SubleaseCancellableWrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease cancellable written notice period.", "label": "Sublease Cancellable Written Notice Period", "terseLabel": "Sublease cancellable written notice period" } } }, "localname": "SubleaseCancellableWrittenNoticePeriod", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ljpc_SubleaseRentExpensePerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublease rent expense per month.", "label": "Sublease Rent Expense Per Month", "terseLabel": "Sublease rent per month" } } }, "localname": "SubleaseRentExpensePerMonth", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_SubleaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease term.", "label": "Sublease Term", "terseLabel": "Sublease term" } } }, "localname": "SubleaseTerm", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ljpc_SupplyAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply agreement term.", "label": "Supply Agreement Term", "terseLabel": "Supply agreement term" } } }, "localname": "SupplyAgreementTerm", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "ljpc_TetraphasePharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tetraphase Pharmaceuticals, Inc. [Member]", "label": "Tetraphase Pharmaceuticals Inc. [Member]", "terseLabel": "Tetraphase Pharmaceuticals, Inc." } } }, "localname": "TetraphasePharmaceuticalsInc.Member", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_TetraphasePharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tetraphase Pharmaceuticals, Inc. [Member]", "label": "Tetraphase Pharmaceuticals Inc [Member]", "terseLabel": "Tetraphase Pharmaceuticals, Inc." } } }, "localname": "TetraphasePharmaceuticalsIncMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ljpc_TwoThousandandThirteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand and Thirteen Plan [Member]", "label": "Two Thousandand Thirteen Plan [Member]", "terseLabel": "2013 Equity Plan [Member]" } } }, "localname": "TwoThousandandThirteenPlanMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "ljpc_UnrealizedGainsOnShortTermInvestments": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrealized Gains On Short-Term Investments", "label": "Unrealized Gains On Short Term Investments", "terseLabel": "Unrealized gains on short-term investments" } } }, "localname": "UnrealizedGainsOnShortTermInvestments", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ljpc_UpfrontCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront Cash Payment.", "label": "Upfront Cash Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "UpfrontCashPayment", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ljpc_WalthamMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Waltham, Massachusetts.", "label": "Waltham Massachusetts [Member]", "terseLabel": "Waltham Sublease" } } }, "localname": "WalthamMassachusettsMember", "nsuri": "http://www.lajollapharmaceutical.com/20210630", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r56", "r89" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r160", "r219", "r222", "r365" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r160", "r219", "r222", "r365" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r157", "r219", "r220", "r330", "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r157", "r219", "r220", "r330", "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r158", "r159", "r219", "r221", "r364", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r158", "r159", "r219", "r221", "r364", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r24", "r161", "r162" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r45" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r188" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite Lived Intangible Assets Weighted Average Useful Life", "terseLabel": "Weighted-average Years" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r94", "r95", "r96", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r229", "r231", "r254", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r231", "r246", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r79", "r175", "r183" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r87", "r146", "r149", "r155", "r164", "r290", "r293", "r301", "r336", "r351" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r55", "r87", "r164", "r290", "r293", "r301" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r232", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r226", "r227", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the business acquisition agreement was executed, in CCYY-MM-DD format.", "label": "Business Acquisition Date Of Acquisition Agreement1", "terseLabel": "Business acquisition, date of acquisition agreement" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Business Acquisition Description Of Acquired Entity", "terseLabel": "Business acquisition, description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination Acquisition Related Costs", "terseLabel": "Additional aggregate payments" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r285", "r286", "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination Consideration Transferred1", "terseLabel": "Upfront cash for acquisition", "verboseLabel": "Cash" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition of Tetraphase Pharmaceuticals, Inc" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets", "terseLabel": "Estimated fair value of assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10120.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease obligation assumed in business combination.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation", "negatedLabel": "Lease liabilities, current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10010.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10040.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10020.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10100.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10080.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets", "terseLabel": "Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10030.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities", "terseLabel": "Estimated fair value of liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10140.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other", "negatedLabel": "Other noncurrent liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10050.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r282" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net", "totalLabel": "Total Purchase Price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r83", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r39", "r81" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents And Short Term Investments [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r81", "r82" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r302" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r85", "r87", "r109", "r113", "r116", "r118", "r120", "r128", "r129", "r130", "r164", "r301" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r195", "r341", "r356" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value (USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r224", "r225", "r228", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Equity Incentive Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r160", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r160", "r298", "r299", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r133", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r160", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r136", "r137", "r138", "r139", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r83", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.", "label": "Convertible Preferred Stock Shares Reserved For Future Issuance", "terseLabel": "Convertible Preferred Stock, Shares Reserved for Future Issuance" } } }, "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r67", "r330" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of product sales, license revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Product Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r65" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs And Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditCardMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service, paid directly to merchant by card issuer, and later paid by cardholder to card issuer.", "label": "Credit Card [Member]", "terseLabel": "Credit Card" } } }, "localname": "CreditCardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Deferred Royalty Obligation" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r337", "r338", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r311", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Promissory note" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r90", "r202", "r205", "r206", "r207", "r310", "r311", "r313", "r348" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r310", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "terseLabel": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r42", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Deferred Finance Costs Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r79", "r186" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r63", "r99", "r100", "r101", "r102", "r103", "r107", "r109", "r118", "r119", "r120", "r124", "r125", "r344", "r359" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted Other Disclosures [Abstract]", "terseLabel": "Shares used in computing earnings (loss) per share" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r63", "r99", "r100", "r101", "r102", "r103", "r109", "r118", "r119", "r120", "r124", "r125", "r344", "r359" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r121", "r122", "r123", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOnFutureCashFlowsAmount": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on cash flows.", "label": "Effect On Future Cash Flows Amount", "terseLabel": "Future cash payments" } } }, "localname": "EffectOnFutureCashFlowsAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Employee Benefits And Share Based Compensation Noncash", "terseLabel": "Reversal of non-cash-stock-based compensation expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Recognized weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unamortized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r94", "r95", "r96", "r98", "r104", "r106", "r127", "r165", "r201", "r208", "r249", "r250", "r251", "r266", "r267", "r303", "r304", "r305", "r306", "r307", "r308", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentToInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value adjustment to acquisition-date inventory allocated (included) to (in) reported pro forma earnings (supplemental pro forma information).", "label": "Fair Value Adjustment To Inventory [Member]", "terseLabel": "Fair Value Step-Up Adjustment to Inventory" } } }, "localname": "FairValueAdjustmentToInventoryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite Lived Intangible Asset Useful Life", "terseLabel": "Useful Life (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r182" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r176", "r178", "r182", "r184", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r182", "r332" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Total intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r176", "r181" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r182", "r331" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "totalLabel": "Total intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r79" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain Loss On Disposition Of Assets1", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r171", "r172", "r335" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails": { "order": 10090.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill And Intangible Asset Impairment", "terseLabel": "Goodwill impairment charges" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r83", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill And Intangible Assets Goodwill Policy", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r83", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill And Intangible Assets Intangible Assets Policy", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r79", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment Of Intangible Assets Excluding Goodwill", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r61", "r146", "r148", "r151", "r154", "r156", "r333", "r342", "r347", "r360" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r262", "r264", "r265", "r268", "r270", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r105", "r106", "r145", "r261", "r269", "r271", "r361" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income taxes", "verboseLabel": "Provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase Decrease In Stockholders Equity Roll Forward", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r114", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable To Conversion Of Preferred Stock", "terseLabel": "Issuance of common stock up on conversion of preferred stock" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r110", "r111", "r112", "r120" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements", "terseLabel": "Stock options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r174", "r180" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r340", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity).", "label": "Interest And Dividends Payable Current And Noncurrent", "terseLabel": "Accrued interest expense" } } }, "localname": "InterestAndDividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseBorrowings": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest expense on all borrowings.", "label": "Interest Expense Borrowings", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseBorrowings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r345" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income Expense Net", "totalLabel": "Total other (expense) income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Income Expense Net [Abstract]", "terseLabel": "Other (expense) income" } } }, "localname": "InterestIncomeExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r168" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "order": 10030.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r54" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r168" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "order": 10010.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory Raw Materials Net Of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r54", "r92", "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r168" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "order": 10020.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory Work In Process Net Of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r166" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write Down", "terseLabel": "Inventory fair value step-up adjustment included in cost of product sales", "verboseLabel": "Inventory fair value step up adjustment" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r321", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "terseLabel": "Lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r87", "r150", "r164", "r291", "r293", "r294", "r301" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r87", "r164", "r301", "r339", "r354" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r87", "r164", "r291", "r293", "r294", "r301" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License Revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Loans Payable" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r196" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r77", "r80" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r58", "r59", "r62", "r80", "r87", "r97", "r99", "r100", "r101", "r102", "r105", "r106", "r117", "r146", "r148", "r151", "r154", "r156", "r164", "r301", "r343", "r358" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r146", "r148", "r151", "r154", "r156" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r315" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails2": { "order": 10020.0, "parentTag": "ljpc_LesseeOperatingLeaseLiabilityPaymentsExcludingLeaseOperatingCostDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "verboseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsExcludingOperatingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r316", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating lease, cash payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r314" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Operating lease weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r319", "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating lease weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r45" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails": { "order": 10060.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other noncurrent liabilities", "totalLabel": "Total other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNoncurrentLiabilitiesDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Noncurrent [Abstract]" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities Table [Text Block]", "terseLabel": "Schedule of Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period.", "label": "Payments For Proceeds From Businesses And Interest In Affiliates", "terseLabel": "Proceeds from businesses and interest in affiliates" } } }, "localname": "PaymentsForProceedsFromBusinessesAndInterestInAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments For Royalties", "terseLabel": "Royalties payments" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r71" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments To Acquire Short Term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r232", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value (USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Assets [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r37", "r38" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r7", "r169", "r170" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds From Collaborators", "terseLabel": "Milestone payments received" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r72" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds from issuance of common stock under 2013 Equity Plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds From Sale Of Property Plant And Equipment", "terseLabel": "Proceeds from the sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r187" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r189", "r355" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r187" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction Other Revenues From Transactions With Related Party", "terseLabel": "Other income\u2014related party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedPartyAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Other Income\u2014Related Party" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureOtherIncomeRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments Of Debt", "terseLabel": "Royalty payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureDeferredRoyaltyObligationAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research And Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research And Development Arrangement Contract To Perform For Others [Line Items]", "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r257", "r384" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research And Development Expense Excluding Acquired In Process Cost", "terseLabel": "Milestone payment" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r82", "r334", "r352" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash And Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash And Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r17", "r82", "r374" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring And Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring And Related Activities Disclosure [Text Block]", "terseLabel": "Company-wide Realignments" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignment" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost And Reserve [Line Items]", "terseLabel": "Restructuring Cost And Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r208", "r252", "r353", "r369", "r370" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r94", "r95", "r96", "r98", "r104", "r106", "r165", "r249", "r250", "r251", "r266", "r267", "r366", "r368" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r143", "r144", "r147", "r152", "r153", "r157", "r158", "r160", "r218", "r219", "r330" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r84", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r66", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Parties", "terseLabel": "Net sales from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r60", "r87", "r143", "r144", "r147", "r152", "r153", "r157", "r158", "r160", "r164", "r301", "r347" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r137", "r160" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "U.S. Net Product Sales" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncSummaryOfPurchasePriceAllocationAsOfAcquisitionDateDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule Of Business Acquisitions By Acquisition [Text Block]", "terseLabel": "Summary of Purchase Price Allocation as of Acquisition Date" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r231", "r245", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r231", "r245", "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r176", "r181", "r331" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r176", "r181" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]", "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r14", "r82", "r334", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Schedule Of Restricted Cash And Cash Equivalents [Table]", "terseLabel": "Schedule Of Restricted Cash And Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule Of Restructuring And Related Costs [Table]", "terseLabel": "Schedule Of Restructuring And Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureCompanyWideRealignmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r232", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r235", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Equity Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r52", "r85", "r128", "r129", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r139", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]", "terseLabel": "Schedule of Concentration Risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Number of shares reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Cancelled/Forfeited, Shares underlying stock options and restricted stock awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted, Shares underlying stock options and restricted stock awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r237", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares)", "periodStartLabel": "Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in the weighted average exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price", "terseLabel": "Change of equity awards outstanding or equity awards, exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityParentheticalDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Shares Underlying Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding ending balance, Weighted - average exercise price (usd per share)", "periodStartLabel": "Outstanding beginning balance, Weighted - average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted- Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r230", "r234" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted - average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Cancelled/forfeited, Weighted - average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted, Weighted - average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software And Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r85", "r87", "r109", "r113", "r116", "r118", "r120", "r128", "r129", "r130", "r164", "r201", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r53", "r94", "r95", "r96", "r98", "r104", "r106", "r127", "r165", "r201", "r208", "r249", "r250", "r251", "r266", "r267", "r303", "r304", "r305", "r306", "r307", "r308", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r94", "r95", "r96", "r127", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r22", "r23", "r201", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r201", "r208", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised, Shares underlying stock options and restricted stock awards (in shares)", "terseLabel": "Issuance of common stock under 2013 Equity Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r22", "r23", "r201", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r53", "r201", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock under 2013 Equity Plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r87", "r163", "r164", "r301" ], "calculation": { "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Shareholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r86", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r309", "r329" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r309", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r309", "r329" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Account Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Liquidation Preference", "terseLabel": "Preferred stock, liquidation", "verboseLabel": "Preferred stock, liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureAcquisitionOfTetraphasePharmaceuticalsIncAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r260", "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r134", "r135", "r140", "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Potential common shares that were included in the calculation of diluted earnings per share" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/DisclosureEarningsLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r108", "r120" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r107", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.7,8)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r385": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r386": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r387": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r388": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r389": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r57": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 69 0001564590-21-041197-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-041197-xbrl.zip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Ð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�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end

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Jul. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-36282
Entity Registrant Name	LA JOLLA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	33-0361285
Entity Address, Address Line One	201 Jones Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	617
Local Phone Number	715-3600
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	LJPC
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Shell Company	false
Entity Common Stock, Shares Outstanding		27,488,137
Entity Central Index Key	0000920465
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 45,888	$ 21,221
Accounts receivable, net	8,596	5,834
Inventory, net	5,481	6,013
Prepaid expenses and other current assets	5,201	3,388
Total current assets	65,166	36,456
Goodwill	20,123	20,123
Intangible assets, net	14,097	14,873
Right-of-use lease assets	419	536
Property and equipment, net	163	215
Restricted cash	40	40
Total assets	100,008	72,243
Current liabilities:
Accounts payable	1,846	2,762
Accrued expenses	12,175	6,494
Accrued payroll and related expenses	1,912	2,878
Lease liabilities, current portion	168	204
Total current liabilities	16,101	12,338
Deferred royalty obligation, net	124,470	124,437
Accrued interest expense on deferred royalty obligation, less current portion	22,136	19,111
Lease liabilities, less current portion	251	332
Other noncurrent liabilities	4,493	4,112
Total liabilities	167,451	160,330
Commitments and contingencies (Note 6)
Shareholders’ deficit:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	987,249	984,756
Accumulated deficit	(1,058,601)	(1,076,752)
Total shareholders’ deficit	(67,443)	(88,087)
Total liabilities and shareholders’ deficit	100,008	72,243
Series C-1 Convertible Preferred Stock
Shareholders’ deficit:
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020	$ 3,906	$ 3,906

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Common stock, par value (USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,482,231	27,402,648
Common stock, shares outstanding (in shares)	27,482,231	27,402,648
Series C-1 Convertible Preferred Stock
Preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	11,000	11,000
Preferred stock, shares issued (in shares)	3,906	3,906
Preferred stock, shares outstanding (in shares)	3,906	3,906
Preferred stock, liquidation	$ 3,906	$ 3,906

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue
Total revenue	$ 16,059,000	$ 5,805,000	$ 50,196,000	$ 13,396,000
Operating expenses
Selling, general and administrative	8,996,000	8,677,000	17,751,000	16,829,000
Research and development	1,114,000	8,781,000	2,672,000	17,964,000
Total operating expenses	12,266,000	18,266,000	28,910,000	36,317,000
Income (loss) from operations	3,793,000	(12,461,000)	21,286,000	(22,921,000)
Other (expense) income
Interest expense	(2,672,000)	(2,470,000)	(5,281,000)	(4,876,000)
Interest income		32,000	2,000	222,000
Other income—related party	2,532,000	0	2,532,000	4,085,000
Other income (expense)	80,000	(693,000)	(370,000)	(693,000)
Total other (expense) income, net	(60,000)	(3,131,000)	(3,117,000)	(1,262,000)
Income (loss) before income taxes	3,733,000	(15,592,000)	18,169,000	(24,183,000)
Provision for income taxes	0	0	18,000	0
Net income (loss)	$ 3,733,000	$ (15,592,000)	$ 18,151,000	$ (24,183,000)
Earnings (loss) per share
Basic	$ 0.14	$ (0.57)	$ 0.66	$ (0.89)
Diluted	$ 0.11	$ (0.57)	$ 0.53	$ (0.89)
Shares used in computing earnings (loss) per share
Basic	27,461	27,326	27,444	27,282
Diluted	34,201	27,326	34,192	27,282
Product Sales
Revenue
Revenue	$ 11,059,000	$ 5,805,000	$ 19,696,000	$ 13,396,000
Operating expenses
Cost of product sales, license revenue	2,156,000	$ 808,000	4,887,000	$ 1,524,000
License Revenue
Revenue
Revenue	$ 5,000,000		30,500,000
Operating expenses
Cost of product sales, license revenue			$ 3,600,000

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Preferred Stock Series C-1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2019	$ (55,990)	$ 3,906	$ 3	$ 977,432	$ (1,037,331)
Beginning Balance (in shares) at Dec. 31, 2019		4	27,195
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,407			2,407
Issuance of common stock under 2013 Equity Plan	305			305
Issuance of common stock under 2013 Equity Plan (in shares)			44
Issuance of common stock under ESPP	200			200
Issuance of common stock under ESPP (in shares)			38
Net income (loss)	(8,591)				(8,591)
Ending Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Ending Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,407			2,407
Issuance of common stock under 2013 Equity Plan	305			305
Issuance of common stock under ESPP	200			200
Issuance of common stock under ESPP (in shares)			38
Net income (loss)	(8,591)				(8,591)
Ending Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Ending Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			44
Beginning Balance at Dec. 31, 2019	(55,990)	$ 3,906	$ 3	977,432	(1,037,331)
Beginning Balance (in shares) at Dec. 31, 2019		4	27,195
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(24,183)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(24,183)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Beginning Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Beginning Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,590			1,590
Issuance of common stock under 2013 Equity Plan	300			300
Issuance of common stock under 2013 Equity Plan (in shares)			50
Issuance of common stock under ESPP	159			159
Issuance of common stock under ESPP (in shares)			32
Net income (loss)	(15,592)				(15,592)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,590			1,590
Issuance of common stock under 2013 Equity Plan	300			300
Issuance of common stock under ESPP	159			159
Issuance of common stock under ESPP (in shares)			32
Net income (loss)	(15,592)				(15,592)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			50
Beginning Balance at Dec. 31, 2020	(88,087)	$ 3,906	$ 3	984,756	(1,076,752)
Beginning Balance (in shares) at Dec. 31, 2020		4	27,403
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,116			1,116
Issuance of common stock under 2013 Equity Plan	154			154
Issuance of common stock under 2013 Equity Plan (in shares)			29
Issuance of common stock under ESPP	81			81
Issuance of common stock under ESPP (in shares)			17
Net income (loss)	14,418				14,418
Ending Balance at Mar. 31, 2021	(72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Ending Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,116			1,116
Issuance of common stock under 2013 Equity Plan	154			154
Issuance of common stock under ESPP	81			81
Issuance of common stock under ESPP (in shares)			17
Net income (loss)	14,418				14,418
Ending Balance at Mar. 31, 2021	(72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Ending Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			29
Beginning Balance at Dec. 31, 2020	$ (88,087)	$ 3,906	$ 3	984,756	(1,076,752)
Beginning Balance (in shares) at Dec. 31, 2020		4	27,403
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)	29,379
Net income (loss)	$ 18,151
Ending Balance at Jun. 30, 2021	(67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	18,151
Ending Balance at Jun. 30, 2021	$ (67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)	29,379
Beginning Balance at Mar. 31, 2021	$ (72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Beginning Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,024			1,024
Issuance of common stock under 2013 Equity Plan	1			1
Issuance of common stock under ESPP	117			117
Issuance of common stock under ESPP (in shares)			33
Net income (loss)	3,733				3,733
Ending Balance at Jun. 30, 2021	(67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,024			1,024
Issuance of common stock under 2013 Equity Plan	1			1
Issuance of common stock under ESPP	117			117
Issuance of common stock under ESPP (in shares)			33
Net income (loss)	3,733				3,733
Ending Balance at Jun. 30, 2021	$ (67,443)	$ 3,906	$ 3	$ 987,249	$ (1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482

Condensed Consolidated Statements of Cash Flows (Unaudited)	3 Months Ended	6 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)
Operating activities
Net income (loss)	$ 3,733,000	$ 18,151,000	$ (24,183,000)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Share-based compensation expense		2,140,000	3,997,000
Depreciation expense		56,000	1,798,000
Non-cash interest expense		3,718,000	3,392,000
Inventory fair value step-up adjustment included in cost of product sales		850,000
Amortization of intangible assets	400,000	776,000	0
Loss on change in fair value of contingent value rights		370,000
Amortization of right-of-use lease assets		117,000	699,000
Loss on disposal of property and equipment			904,000
Unrealized gains on short-term investments			(63,000)
Changes in operating assets and liabilities:
Accounts receivable, net		(2,762,000)	1,117,000
Inventory, net		(318,000)	(909,000)
Prepaid expenses and other current assets		(1,813,000)	1,675,000
Accounts payable		(920,000)	(1,696,000)
Accrued expenses		5,032,000	(3,378,000)
Accrued payroll and related expenses		(966,000)	(2,591,000)
Lease liabilities		(117,000)	(1,357,000)
Net cash provided by (used for) operating activities		24,314,000	(20,595,000)
Investing activities
Proceeds from the sale of property and equipment			2,860,000
Purchases of short-term investments			(2,999,000)
Net cash used for investing activities			(139,000)
Financing activities
Net proceeds from issuance of common stock under 2013 Equity Plan		155,000	605,000
Net proceeds from issuance of common stock under ESPP		198,000	359,000
Net cash provided by financing activities		353,000	964,000
Net increase (decrease) in cash, cash equivalents and restricted cash		24,667,000	(19,770,000)
Cash, cash equivalents and restricted cash, beginning of period		21,261,000	88,729,000
Cash, cash equivalents and restricted cash, end of period	45,928,000	45,928,000	68,959,000
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	45,888,000	45,888,000	68,353,000
Restricted cash	40,000	40,000	606,000
Cash, cash equivalents and restricted cash, end of period	$ 45,928,000	$ 45,928,000	$ 68,959,000

Business - Additional Information (Details) - USD ($) $ in Thousands	Jan. 12, 2021	Jul. 28, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Business Acquisition [Line Items]
Cash and cash equivalents			$ 45,888	$ 21,221	$ 68,353
License Agreement
Business Acquisition [Line Items]
Proceeds from upfront cash payment	$ 22,500
Percentage of refundable tax withholding	15.00%
Commercial milestone payments	$ 109,500
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Upfront cash for acquisition		$ 42,990
Future cash payments		$ 16,000

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021 USD ($) Hospital Customer
Concentration Risk [Line Items]
Number of major customers \| Customer	3
Impairment of intangible assets \| $	$ 0
Goodwill impairment charges \| $	$ 0
U.S.
Concentration Risk [Line Items]
Number of hospitals purchased GIAPREZA \| Hospital	399
Number of hospitals and other healthcare organizations purchased XERAVA \| Hospital	644

Balance Sheet Details - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Raw materials	$ 802	$ 802
Work-in-process	3,636	3,213
Finished goods	1,043	1,998
Total inventory, net	$ 5,481	$ 6,013

Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets [Abstract]
Refundable withholding tax	$ 3,375
Prepaid manufacturing costs	491	$ 930
Prepaid clinical costs	265	820
Prepaid insurance	263	505
Other prepaid expenses and current assets	807	1,133
Total prepaid expenses and other current assets	$ 5,201	$ 3,388

Balance Sheet Details - Property Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Total property and equipment, gross	$ 826	$ 1,352
Accumulated depreciation and amortization	(663)	(1,137)
Total property and equipment, net	163	215
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	313	309
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	310	310
Software and Software Development Costs [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	$ 203	$ 733

Balance Sheet Details - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 15,520	$ 15,520
Accumulated amortization	(1,423)	(647)
Total intangible assets, net	14,097	14,873
Technology
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 14,000	$ 14,000
Useful Life (years)	10 years	10 years
Trade Name
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 1,520	$ 1,520
Useful Life (years)	10 years	10 years

Balance Sheet Details - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrued interest expense on deferred royalty obligation, current portion	$ 4,227	$ 3,567
Deferred revenue	3,037	188
Accrued royalties and in-license fees	1,235	685
Accrued manufacturing costs	1,469	627
Accrued professional fees	942	660
Accrued other	1,265	767
Total accrued expenses	$ 12,175	$ 6,494

Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Liabilities Noncurrent [Abstract]
Paycheck Protection Program loan	$ 2,313	$ 2,302
Fair value of contingent value rights (see Note 11)	2,180	1,810
Total other noncurrent liabilities	$ 4,493	$ 4,112

Deferred Royalty Obligation - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	May 10, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Deferred royalty obligation, net		$ 124,470		$ 124,470		$ 124,437
Interest expense		2,700	$ 2,500	5,300	$ 4,900
Royalty obligation payable		900		900		900
HealthCare Royalty Partners
Debt Instrument [Line Items]
Proceeds from royalty agreement	$ 125,000
Required payment for breach of agreement, payment two	225,000
Required payment for breach of agreement, payment one	125,000
HealthCare Royalty Partners \| Royalty Financing Agreement \| Loans Payable
Debt Instrument [Line Items]
Deferred royalty obligation, net	125,000	124,500		124,500		124,400
Debt issuance costs	$ 700
Unamortized debt discount		500		500		600
Accrued interest expense		26,400		26,400		22,700
Royalty payments		700		1,600
HealthCare Royalty Partners \| Royalty Financing Agreement \| Loans Payable \| Other Noncurrent Liabilities
Debt Instrument [Line Items]
Accrued interest expense		$ 22,100		$ 22,100		$ 19,100
HealthCare Royalty Partners \| Period One
Debt Instrument [Line Items]
Maximum potential royalty payout	10.00%
HealthCare Royalty Partners \| Period Two
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
HealthCare Royalty Partners \| Payout Period
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%

Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Leases [Abstract]
2021	$ 108
2022	181
2023	166
Total future minimum lease payments	455
Less: discount	36
Total lease liabilities	$ 419

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lessee Lease Description [Line Items]
Lease expense			$ 100,000	$ 700,000	$ 200,000	$ 1,400,000
Operating lease, cash payments			$ 51,000	$ 1,000,000.0	$ 100,000	$ 1,900,000
Operating lease weighted-average remaining lease term			2 years 3 months 18 days		2 years 3 months 18 days
Operating lease weighted-average discount rate			3.50%		3.50%
Waltham Sublease
Lessee Lease Description [Line Items]
Expiration date	Nov. 30, 2023
Sublease rent per month	$ 15,000
San Diego Sublease
Lessee Lease Description [Line Items]
Sublease rent per month		$ 12,000
Sublease term		7 years
Sublease cancellable written notice period		30 days
Payments of sublease			$ 28,000		$ 67,000

Shareholders' Equity - Additional Information (Details) - Series C-1 Convertible Preferred Stock - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Preferred stock, shares issued (in shares)	3,906	3,906
Convertible Preferred Stock, Shares Reserved for Future Issuance	6,735,378	6,735,378
Preferred stock, liquidation preference	$ 3,906	$ 3,906

Equity Incentive Plans - Narrative (Details) - USD ($)	6 Months Ended
Equity Incentive Plans - Narrative (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized share-based compensation expense	$ 8,900,000
Recognized weighted average period	3 years
2013 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	9,600,000
Shares available for grant (in shares)	5,514,933	5,478,334
2018 Employee Stock Purchase Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	750,000
Shares available for grant (in shares)	405,564	455,768
Unrecognized share-based compensation expense	$ 0

Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2021 $ / shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Change of equity awards outstanding or equity awards, exercise price	$ 4.28

License Agreements - Additional Information (Details) - USD ($)			1 Months Ended			3 Months Ended			6 Months Ended
	Jul. 13, 2021	Jan. 12, 2021	May 31, 2021	Mar. 31, 2021	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000			$ 30,500,000
George Washington
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment								$ 500,000
Percentage of royalty on net sales									6.00%
Percentage of payments received from sublicensee									15.00%
Royalty payments						400,000	$ 500,000		$ 3,200,000	$ 900,000
Harvard
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales									5.00%
Percentage of payments received from sublicensee									20.00%
Clinical development and regulatory milestones amount payable									$ 15,100,000
Percentage of minimum royalty rate									4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds									7.50%
Royalties payments						1,500,000			$ 1,600,000
Payments related to clinical development and regulatory milestones						0			0
Paratek
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					2.25%
Royalties payments						40,000			$ 100,000
Claim expiration									2023-10
PAION AG
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment		$ 109,500,000
Upfront cash payment		$ 22,500,000
Percentage of refundable tax withholding		15.00%
PAION AG \| Subsequent Event
Research And Development Arrangement Contract To Perform For Others [Line Items]
Supply agreement term	3 years
Everest Medicines Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional regulatory milestone payments receivable						8,000,000.0			$ 8,000,000.0
Sales milestone payments receivable						20,000,000.0			$ 20,000,000.0
Royalties payable description									Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.
Royalties payable period after first commercial sale of product									10 years
Milestone payments received				$ 3,000,000.0
Everest Medicines Limited \| Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from upfront payments			$ 6,800,000
Proceeds from upfront technology transfer payment			4,000,000.0
Proceeds from partial prepayment for XERAVA			2,800,000
Additional technology transfer payment receivable by January 30, 2022			$ 1,000,000.0
Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023			110.00%
Deferred revenue						2,800,000			$ 2,800,000
Everest Medicines Limited \| Commercial Supply Agreement \| License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000.0			$ 5,000,000.0

Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) - USD ($) $ in Thousands	Jul. 28, 2020	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 20,123	$ 20,123
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Cash	$ 42,990
Fair Value of CVRs	2,610
Total Purchase Price	45,600
Cash and cash equivalents	8,778
Accounts receivable	1,187
Inventory	4,767
Prepaid expenses and other current assets	1,218
Property and equipment	58
Right-of-use lease assets	2,302
Restricted cash	699
Identifiable intangible assets	15,520
Goodwill	20,123
Accounts payable	(1,400)
Accrued expenses	(2,979)
Lease liabilities, current portion	(967)
Lease liabilities, less current portion	(1,420)
Other noncurrent liabilities	$ (2,286)

Company-wide Realignments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020 USD ($)
Restructuring Cost And Reserve [Line Items]
Reversal of non-cash-stock-based compensation expense	$ 0.4
Restructuring costs	4.1
Tetraphase Pharmaceuticals, Inc.
Restructuring Cost And Reserve [Line Items]
Restructuring costs	$ 3.1